WO2009052065A1 - Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof - Google Patents

Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof Download PDF

Info

Publication number
WO2009052065A1
WO2009052065A1 PCT/US2008/079760 US2008079760W WO2009052065A1 WO 2009052065 A1 WO2009052065 A1 WO 2009052065A1 US 2008079760 W US2008079760 W US 2008079760W WO 2009052065 A1 WO2009052065 A1 WO 2009052065A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
bipyrrolidinyl
phenyl
oxo
title compound
Prior art date
Application number
PCT/US2008/079760
Other languages
French (fr)
Inventor
Werngard Czechtizky
Zhongli Gao
William J. Hurst
Lothar Schwink
Siegfried Stengelin
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08839473A priority Critical patent/EP2212282B1/en
Priority to JP2010530052A priority patent/JP5255644B2/en
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to MX2010004094A priority patent/MX2010004094A/en
Priority to CN2008801211996A priority patent/CN101903339B/en
Priority to AU2008312638A priority patent/AU2008312638B2/en
Priority to SI200830482T priority patent/SI2212282T1/en
Priority to ES08839473T priority patent/ES2374116T3/en
Priority to DK08839473.9T priority patent/DK2212282T3/en
Priority to RU2010119560/04A priority patent/RU2477719C2/en
Priority to PL08839473T priority patent/PL2212282T3/en
Priority to CA2702482A priority patent/CA2702482C/en
Priority to AT08839473T priority patent/ATE525350T1/en
Priority to NZ584688A priority patent/NZ584688A/en
Priority to BRPI0818626A priority patent/BRPI0818626A2/en
Publication of WO2009052065A1 publication Critical patent/WO2009052065A1/en
Priority to US12/724,035 priority patent/US8618159B2/en
Priority to IL205003A priority patent/IL205003A0/en
Priority to MA32846A priority patent/MA31855B1/en
Priority to HK11100255.7A priority patent/HK1146054A1/en
Priority to HR20110953T priority patent/HRP20110953T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to a series of substituted N-phenyl-bipyrrolidine carboxamides.
  • the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also relates to methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefor.
  • Histamine is a ubiquitous messenger molecule released from mast cells, enterochromaffin-like cells, and neurons.
  • the physiological actions of histamine are mediated by four pharmacologically defined receptors (Hl, H2, H3 and H4). All histamine receptors exhibit seven transmembrane domains and are members of the G-protein-coupled receptor superfamily (GPCRs).
  • GPCRs G-protein-coupled receptor superfamily
  • the Hl receptor was the first member of the histamine receptor family to be pharmacologically defined, with the development of classical antihistamines (antagonists), such as diphenhydramine and fexofenadine.
  • Hl receptor While antagonism of the Hl receptor of the immune system is commonly used for the treatment of allergic reactions, the Hl receptor is also expressed in various peripheral tissues and the central nervous system (CNS). In the brain, Hl is involved in the control of wakefulness, mood, appetite and hormone secretion.
  • H2 receptor is also expressed in the CNS, where it may modulate several processes, including cognition.
  • H2 receptor antagonists have primarily been developed to ameliorate gastric ulcers by inhibiting histamine -mediated gastric acid secretion by parietal cells.
  • Classic H2 antagonists include cimetidine, ranitidine, and famotidine.
  • H4 receptor function remains poorly defined, but may involve immune regulation and inflammatory processes.
  • H3 receptors have also been pharmacologically identified in the CNS, heart, lung, and stomach.
  • the H3 receptor differs significantly from other histamine receptors, exhibiting low sequence homology (Hl : 22%, H2: 21%, H4: 35%).
  • H3 is a presynaptic autoreceptor on histamine neurons in the brain and a presynaptic heteroreceptor in nonhistamine-containing neurons in both the central and peripheral nervous systems.
  • H3 also modulates the release and/or synthesis of other neurotransmitters, including acetylcholine, dopamine, norepinepherin and serotonin.
  • H3 presynaptic modulation of histamine release by H3 allows significant regulation of Hl and H2 receptors in the brain. Modulating multiple neurotransmitter signaling pathways, H3 may contribute to varied physiological processes. Indeed, extensive preclinical evidence indicates that H3 plays a role in cognition, sleep-wake cycle and energy homeostasis. Modulators of H3 function may be useful in the treatment of obesity and central nervous system disorders (Schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, Parkinson's disease, depression, and epilepsy), sleep disorders (narcolepsy and insomnia), cardiovascular disorders (acute myocardial infarction), respiratory disorders (asthma), and gastrointestinal disorders. See generally, Hancock, Biochem. Pharmacol. 2006 Apr 14;71(8): 1103-13 and Esbenshade et al. MoI Interv. 2006 Apr;6(2):77-88, 59.
  • MCH melanin concentrating hormone
  • the compounds of formula (I) are useful as H3 receptor antagonists and/or inverse agonists.
  • the compounds of formula I are not specifically disclosed, nor exemplified, nor are their activity as H3 receptor antagonists/ inverse agonists suggested, in U.S. Patent 7,223,788 as mentioned hereinabove.
  • the compounds of formula (I) are selectively active only at H3 receptors and exhibit low activity at the MCH-I receptor site, which aspect becomes even more apparent from the detailed description that follows.
  • R, R 1 , R 2 and R 3 are the same or different and independently of each other chosen from hydrogen, (Ci-C 4 )alkyl or CF 3 ;
  • R 4 is selected from the group consisting of dimethylaminomethyl, methanesulfonylmethyl, phenoxymethyl, vinylbenzene, ethynylbenzene, vinylpyridine, phenyl, benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro-benzofuranyl, benzodioxolyl, oxo-chromenyl, dihydrobenzo-dioxinyl, dioxo-tetrahydro-lH-benzo[e]diazepinyl, imidazopyridinyl, benzotriazolyl, benzoimidazolyl, oxo-dihydro-benzoimidazolyl, indolyl, indazolyl, naphthyridinyl, quinolinyl, benzoimidazothiazolyl, pyridinyl, pyrimidinyl, pyrrolyl, triazolyl
  • This invention further includes various salts of the compounds of formula (I) including various enantiomers or diastereomers of compounds of formula (I).
  • various pharmaceutical compositions comprising one or more compounds of formula (I) as well as their therapeutic use in alleviating various diseases which are mediated in-part and/or fully by H3 receptors.
  • (Ci-C 6 )alkyl includes methyl and ethyl groups, and straight-chained or branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and tert-butyl.
  • (Ci-C 4 )dialkylcarbamoyl(Ci-C 4 )alkyl "mono- or di-(Ci-C 4 )alkylamino(Ci-C 4 )alkyl", "amino(Ci-C 4 )alkylcarbonyl” “diphenyl(Ci-C 4 )alkyl”, "phenyl(Ci-C 4 )alkyl",
  • phenylcarboyl(Ci-C 4 )alkyl and "phenoxy(Ci-C 4 )alkyl” are to be construed accordingly.
  • cycloalkyl includes all of the known cyclic radicals.
  • Representative examples of “cycloalkyl” include without any limitation cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
  • Derived expressions such as “cycloalkoxy”, “cycloalkylalkyl”, “cycloalkylaryl”, “cycloalkylcarbonyl” are to be construed accordingly.
  • (C 2 -C 6 )alkenyl includes ethenyl and straight-chained or branched propenyl, butenyl, pentenyl and hexenyl groups.
  • (C 2 - C6)alkynyl includes ethynyl and propynyl, and straight-chained or branched butynyl, pentynyl and hexynyl groups.
  • (Ci-C 4 )acyl shall have the same meaning as “(Ci-C6)alkanoyl", which can also be represented structurally as “R-CO-,” where R is a (Ci-C 3 )alkyl as defined herein. Additionally, “(Ci-C 3 )alkylcarbonyl” shall mean same as (C 1 - C 4 )acyl. Specifically, “(Ci-C 4 )acyl” shall mean formyl, acetyl or ethanoyl, propanoyl, n- butanoyl, etc. Derived expressions such as “(Ci-C 4 )acyloxy” and "(Ci-C 4 )acyloxyalkyl” are to be construed accordingly.
  • (Ci-C 6 )perfluoroalkyl means that all of the hydrogen atoms in said alkyl group are replaced with fluorine atoms.
  • Illustrative examples include trifluoromethyl and pentafluoroethyl, and straight-chained or branched heptafluoropropyl, nonafluorobutyl, undecafluoropentyl and tridecafluorohexyl groups.
  • Derived expression, "(Ci-C6)perfluoroalkoxy” is to be construed accordingly.
  • (C 6 -C io)aryl means substituted or unsubstituted phenyl or naphthyl.
  • substituted phenyl or naphthyl include o-, p-, m-tolyl, 1,2-, 1,3-, 1,4-xylyl, 1-methylnaphthyl, 2-methylnaphthyl, etc.
  • Substituted phenyl or “substituted naphthyl” also include any of the possible substituents as further defined herein or one known in the art. Derived expression, "(C 6 -Cio)arylsulfonyl,” is to be construed accordingly.
  • (C 6 -Cio)aryl(Ci-C 4 )alkyl means that the (Ce-Cio)aryl as defined herein is further attached to (Ci-C 4 )alkyl as defined herein.
  • Representative examples include benzyl, phenylethyl, 2-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl and the like.
  • heteroaryl includes all of the known heteroatom containing aromatic radicals.
  • Representative 5-membered heteroaryl radicals include furanyl, thienyl or thiophenyl, pyrrolyl, isopyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, isothiazolyl, and the like.
  • Representative 6-membered heteroaryl radicals include pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like radicals.
  • bicyclic heteroaryl radicals include, benzofuranyl, benzothiophenyl, indolyl, quinolinyl, isoquinolinyl, cinnolyl, benzimidazolyl, indazolyl, pyridofuranyl, pyridothienyl, and the like radicals.
  • heterocycle includes all of the known reduced heteroatom containing cyclic radicals.
  • Representative 5-membered heterocycle radicals include tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, 2-thiazolinyl, tetrahydrothiazolyl, tetrahydrooxazolyl, and the like.
  • Representative 6-membered heterocycle radicals include piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and the like.
  • Various other heterocycle radicals include, without limitation, aziridinyl, azepanyl, diazepanyl, diazabicyclo[2.2.1]hept-2-yl, and triazocanyl, and the like.
  • Halogen or “halo” means chloro, fluoro, bromo, and iodo.
  • patient means a warm blooded animal, such as for example rat, mice, dogs, cats, guinea pigs, and primates such as humans.
  • the expression "pharmaceutically acceptable carrier” means a nontoxic solvent, dispersant, excipient, adjuvant, or other material which is mixed with the compound of the present invention in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to the patient.
  • a pharmaceutical composition i.e., a dosage form capable of administration to the patient.
  • pharmaceutically acceptable oil typically used for parenteral administration.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfamic acid, sulfuric acid, methanesulfonic acid, 2-hydroxyethanesulfonic acid, p- toluenesulfonic acid, fumaric acid, maleic acid, hydroxymaleic acid, malic acid, ascorbic acid, succinic acid, glutaric acid, acetic acid, propionic acid, salicylic acid, cinnamic acid, 2- phenoxybenzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, 2- phenoxybenzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, 2- phenoxybenzoic acid, hydroxybenzoic acid, phenylacetic
  • the acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate can also be formed.
  • the salts so formed may present either as mono- or di- acid salts and can exist substantially anhydrous or can be hydrated.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts, and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
  • prodrug shall have the generally accepted meaning in the art.
  • One such definition includes a pharmacologically inactive chemical entity that when metabolized or chemically transformed by a biological system such as a mammalian system is converted into a pharmacologically active substance.
  • stereoisomers is a general term used for all isomers of the individual molecules that differ only in the orientation of their atoms in space. Typically it includes mirror image isomers that are usually formed due to at least one asymmetric center, (enantiomers). Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereoisomers, also certain individual molecules may exist as geometric isomers (cis/trans). Similarly, certain compounds of this invention may exist in a mixture of two or more structurally distinct forms that are in rapid equilibrium, commonly known as tautomers.
  • tautomers include keto-enol tautomers, phenol-keto tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
  • 'R' and 'S' are used as commonly used terms in organic chemistry to denote specific configuration of a chiral center.
  • 'R rectus
  • 'S' sinister
  • 'R rectus
  • 'S' sinister
  • the priority of groups is based upon sequence rules wherein prioritization is first based on atomic number (in order of decreasing atomic number). A listing and discussion of priorities is contained in Stereochemistry of Organic Compounds, Ernest L.
  • solvate means that an aggregate that consists of a solute ion or molecule with one or more solvent molecules.
  • a "hydrate” means that a solute ion or molecule with one or more water molecules.
  • substituted is contemplated to include all permissible substituents of organic compounds.
  • substituted means substituted with one or more substituents independently selected from the group consisting of (Ci_Ce)alkyl, (C 2 -Ce)alkenyl, (Ci_C 6 )perfluoroalkyl, phenyl, hydroxy, -CO 2 H, an ester, an amide, (Ci-Ce)alkoxy, (Ci-Ce)thioalkyl, (Ci-C6)perfluoroalkoxy, -NH 2 , Cl, Br, I, F, -NH-lower alkyl, and -N(lower alkyl) 2 .
  • substituents independently selected from the group consisting of (Ci_Ce)alkyl, (C 2 -Ce)alkenyl, (Ci_C 6 )perfluoroalkyl, phenyl, hydroxy, -CO 2 H, an ester, an amide, (Ci-Ce)alkoxy, (Ci-Ce)thioal
  • “Therapeutically effective amount” means an amount of the compound which is effective in treating the named disease, disorder or condition.
  • Treating refers to:
  • R, Ri, R 2 and R 3 are the same or different and independently of each other chosen from hydrogen, (Ci-C 4 )alkyl or CF 3 ;
  • R 4 is selected from the group consisting of dimethylaminomethyl, methanesulfonylmethyl, phenoxymethyl, vinylbenzene, ethynylbenzene, vinylpyridine, phenyl, benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro-benzofuranyl, benzodioxolyl, oxo-chromenyl, dihydrobenzo-dioxinyl, dioxo-tetrahydro-lH-benzo[e]diazepinyl, imidazopyridinyl, benzotriazolyl, benzoimidazolyl, oxo-dihydro-benzoimidazolyl, indolyl, indazolyl, naphthyridiny
  • This invention further includes various salts of the compounds of formula (I) including various enantiomers or diastereomers of compounds of formula (I). As noted hereinabove and by way of specific examples hereafter all of the salts that can be formed including pharmaceutically acceptable salts are part of this invention. As also noted hereinabove and hereafter all of the conceivable enantiomeric and diastereomeric forms of compounds of formula (I) are part of this invention.
  • R 4 is phenyl or phenyl substituted with one or more groups selected from fluorine, chlorine, methyl, isopropyl, propoxyethyl, CF 3 , CN, methoxy, difluoromethoxy, methanesulfonyl, sulfamoyl, dimethylamino, N-formyl-methylamino, carboxyphenoxy, oxo-dihydro-pyridinyl, pyrimidinyl-methylamino, pyrazolyl, 3,5-dimethyl-pyrazolyl, imidazolyl, triazolyl, oxazolyl, N-acetyl-piperidinyl, morpholinylmethyl or 2-oxo- pyrrolidinyl.
  • R 4 is selected from benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro- benzofuranyl, benzodioxolyl, dihydrobenzo-dioxinyl, dioxo-tetrahydro-lH- benzo[e]diazepinyl or oxo-chromenyl, in which said R 4 is optionally substituted one or more times with chlorine, methyl or methoxy.
  • R 4 is pyridinyl or pyrimidinyl, which is optionally substituted one or more times with chlorine, methyl, 2-hydroxyethylamino, 2-methoxyethylamido, benzyloxymethyl or morpholinyl.
  • R 4 is selected from imidazopyridinyl, benzotriazolyl, benzoimidazolyl, oxo- dihydro-benzoimidazolyl, indolyl, indazolyl, naphthyridinyl, quinolinyl or benzoimidazothiazolyl, in which said R 4 is optionally substituted one or more times with fluorine, chlorine, hydroxy, methyl, isopropyl, methoxy or pyridinyl.
  • R 4 is selected from pyrrolyl, triazolyl, thienyl or thiazolyl, in which said R 4 is optionally substituted one or more times with methyl, phenyl, benzoyl or pyridinyl.
  • the compound of this invention may be represented by a specific stereoisomeric form of formula (II):
  • R, R 1 , R 2 , R3 and R 4 are as defined hereinabove.
  • 6-methoxy-benzofuran-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ? -yl)- phenyl]-amide;
  • 6-chloro-4-oxo-4H-chromene-2-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r- yl)-phenyl]-amide
  • 6-methyl-4-oxo-4H-chromene-2-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-
  • 6-methyl-pyridine-2-carboxylic acid [2-methyl-4-(2(S)-methyl-[ 1 ,3 '(S)]bipyrrolidinyl- 1 ? -yl)- phenyl]-amide; 5-chloro-6-(2-hydroxy-ethylamino)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl] -nicotinamide;
  • 2-pyridin-3-yl-thiazole-4-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl]-amide
  • 2-pyridin-4-yl-thiazole-4-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3 'Jbipyrrolidinyl- 1 ? -yl)- phenyl]-amide;
  • the compounds of this invention can be synthesized by any of the procedures known to one skilled in the art. Specifically, several of the starting materials used in the preparation of the compounds of this invention are known or are themselves commercially available. The compounds of this invention and several of the precursor compounds may also be prepared by methods used to prepare similar compounds as reported in the literature and as further described herein. For instance, as stated hereinabove a few of the structurally similar compounds have been disclosed in U. S. Patent No. 7,223,788. Also, see R. C. Larock, "Comprehensive Organic Transformations," VCH publishers, 1989.
  • suitable amine protecting groups include without any limitation sulfonyl (e.g., tosyl), acyl (e.g., benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g., benzyl), which may be removed subsequently by hydrolysis or hydrogenation as appropriate.
  • sulfonyl e.g., tosyl
  • acyl e.g., benzyloxycarbonyl or t-butoxycarbonyl
  • arylalkyl e.g., benzyl
  • Scheme 1 illustrates the preparation of the intermediate [1, 3']- pyrrolidinyl-pyrrolidine of formula (4), wherein R is as defined herein.
  • step 1 Scheme 1, suitably protected (for example tert-butyloxycarbonyl (boc)) pyrrolidinone of formula (1) is condensed with a desired substituted pyrrolidine of formula (2) by any of the known reductive amination procedures to from an intermediate of formula (3).
  • condensation reactions are generally carried out in the presence of reducing agents such as triacetoxyborohydride in an inert atmosphere, such as nitrogen atmosphere.
  • the reaction can be carried out either at sub-ambient, ambient or super-ambient reaction temperatures and pressures. Typically, such reactions are carried out at room temperature at atmospheric pressure of nitrogen.
  • the reaction mixture is then worked-up using procedures known to one skilled in the art to isolate the intermediate of formula (3).
  • step 2 Scheme 1, the intermediate (3) is then de-protected to form the desired [1, 3']-pyrrolidinyl-pyrrolidine of formula (4).
  • Such deprotection reactions are generally carried out under acidic conditions, for example, in the presence of hydrochloric acid at sub-ambient to ambient temperatures, for example in the temperature range of about -10 0 C to room temperature.
  • suitable reaction temperatures can also be used depending upon the nature of the intermediate of formula (3).
  • step 1 [l,3']-pyrrolidinyl-pyrrolidine of formula (9), wherein R is as defined herein.
  • step 2 suitably protected (for example boc) pyrrolidine alcohol of formula (5) is treated with p-toluene sulfonyl chloride to form intermediate of formula (6).
  • This reaction can be carried out using any of the procedures known to one skilled in the art, such as for example carrying out the reaction in the presence of a suitable base such as triethylamine and DMAP in a suitable organic solvent, preferably an aprotic solvent such as dichloromethane at sub- ambient or ambient temperature conditions.
  • step 2 Scheme 2, the intermediate of formula (6) is condensed with a desired pyrrolidine of formula (7).
  • condensation reactions can be carried out using any of the procedures known to one skilled in the art in order to obtain the intermediate of formula (8).
  • condensation reactions are carried out in the presence of a base such as potassium carbonate in the presence of solvents such as acetonitrile at ambient to super- ambient temperature conditions.
  • step 3 the intermediate of formula (8) is then reacted with an acid, such as hydrochloric acid in a suitable solvent, such as dioxane, to form the desired stereospecific isomer of [l,3']-pyrrolidinyl-pyrrolidine intermediate of formula (9).
  • an acid such as hydrochloric acid
  • a suitable solvent such as dioxane
  • Scheme 3 illustrates the preparation of amino-phenyl-pyrrolidinyl-pyrrolidine intermediate of formula (12), wherein R, Ri and R 2 are as defined herein.
  • step 1 Scheme 1
  • condensation reaction can again be carried out using any of the procedures known to one skilled in the art.
  • condensation reaction can be carried out in a polar solvent such as DMSO in the presence of a base such as potassium carbonate at ambient to super-ambient temperature conditions.
  • step 2 Scheme 3, intermediate of formula (11) is reduced by hydrogenation or other known chemical methods, such as using tin dichloride in hydrochloric acid, to form the key intermediate (12).
  • Scheme 4 illustrates the preparation of compounds of formula (I) of this invention using either Method A or Method B depending upon the availability of desired carboxylic acid of formula R 4 -CO 2 H either in the form of the acid itself or its acid chloride, wherein R, R 1 , R 2 and R 4 are as described herein and R3 is hydrogen.
  • the acid chloride of formula (13) can be reacted with the intermediate (12) using any of the conditions known to one skilled in the art.
  • such conditions include without any limitations reaction of the acid chloride with the intermediate of formula (12) in a suitable organic solvent such as for example dichloromethane in the presence of a suitable base such as pyridine.
  • a suitable organic solvent such as for example dichloromethane
  • a suitable base such as pyridine.
  • Such reactions are generally carried out at sub- ambient temperature conditions, for example around 0 0 C, however ambient to super-ambient temperature conditions may also be suitable in certain situations depending upon the nature of the acid chloride and the intermediate (12).
  • the carboxylic acid of formula (14) can be reacted with the intermediate of formula (12) under various reaction conditions known to one skilled in the art.
  • the acid of formula (14) is reacted with intermediate of formula (12) at sub-ambient temperature conditions in the presence of suitable reagents such as for example a mixture of N-methylmorpholine, 1-hydroxybenzotriazole and EDC.
  • suitable reagents such as for example a mixture of N-methylmorpholine, 1-hydroxybenzotriazole and EDC.
  • the compounds of this invention can readily be converted into salts. More particularly, the compounds of the present invention are basic, and as such compounds of this invention are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof. Acid addition salts may be a more convenient form for use; and, in practice, use of the salt form inherently amounts to use of the free base form.
  • the acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions.
  • a specific disease, a disorder or a condition that can be treated with the compound of this invention include, without any limitation the following: sleep-related disorders (specific examples include without any limitation narcolepsy, circadian rhythm sleep disorders, obstructive sleep apnea, periodic limb movement and restless leg syndrome, excessive sleepiness and drowsiness due to medication side-effect, etc.), neurological disorders (specific examples that may be enumerated include but not limited to dementia, Alzheimer's disease, multiple sclerosis, epilepsy and neuropathic pain), neuropsychological and cognitive disorders (a few of the specific examples include without any limitation include schizophrenia, attention deficit/hyperactivity disorder, Alzheimer's disease, depression, seasonal affective disorder, and cognitive impairment).
  • sleep-related disorders specifically examples include without any limitation narcolepsy, circadian rhythm sleep disorders, obstructive sleep apnea, periodic limb movement and restless leg syndrome, excessive sleepiness and drowsiness due to medication side-effect, etc.
  • neurological disorders specifically examples that may
  • the compounds of formula (I) bind to the H3 receptors and demonstrate inverse agonism versus H3 functional activity. Therefore, the compounds of this invention may have utility in the treatment of diseases or conditions ameliorated with H3 receptor ligands. More specifically, the compounds of the present invention are H3 receptor ligands that modulate function of the H3 receptor by antagonizing the activity of the receptor. Further, the compounds of this invention may be inverse agonists that inhibit the basal activity of the receptor or they may be antagonists that completely block the action of receptor-activating agonists. Additionally, the compounds of this invention may also be partial agonists that partially block or partially activate the H3 receptor or they may be agonists that activate the receptor.
  • the compounds of this invention may act differentially as antagonists, inverse agonists and/or partial agonists depending on functional output, histamine tone and or tissue context. Accordingly, the differential activities of these compounds may allow for utility to ameliorate multiple disease states as specifically enumerated above.
  • a method of treating a disease in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula (I).
  • the compounds of this invention may be used to treat any disease caused by the effects of H3 receptors. That is, as noted above, the compounds of the present invention are modulators of H3 receptors and may be effectively administered to ameliorate any disease state which is mediated all or in part by H3 receptors.
  • the compounds used in the method of this invention are capable of inhibiting the effects of H3 receptor and thereby alleviating the effects and/or conditions caused due to the activity of H3.
  • the compounds of this invention can be administered by any of the methods known in the art. Specifically, the compounds of this invention can be administered by oral, intramuscular, subcutaneous, rectal, intratracheal, intranasal, intraperitoneal or topical route.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I), including enantiomers, stereoisomers, and tautomers of said compound and pharmaceutically acceptable salts, solvates or derivatives thereof, with said compound having the general structure shown in formula I as described herein.
  • the pharmaceutical compositions of this invention feature H3 inhibitory activity and thus are useful in treating any disease, condition or a disorder caused due to the effects of H3 in a patient.
  • all of the preferred embodiments of the compounds of this invention as disclosed herein can be used in preparing the pharmaceutical compositions as described herein.
  • the pharmaceutical compositions of this invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
  • the compositions may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
  • An erodible polymer containing the active ingredient may be envisaged.
  • the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water
  • a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate
  • This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
  • Flavored unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient.
  • the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
  • compositions of this invention can be administered by any of the methods known in the art.
  • the pharmaceutical compositions of this invention can be administered by oral, intramuscular, subcutaneous, rectal, intratracheal, intranasal, intraperitoneal or topical route.
  • the preferred administrations of the pharmaceutical composition of this invention are by oral and intranasal routes. Any of the known methods to administer pharmaceutical compositions by an oral or an intranasal route can be used to administer the composition of this invention.
  • a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 20 mg/kg per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day.
  • Flash chromatography is performed using Alltech prepacked silica gel cartridges.
  • the 1 H NMR spectra are run at 300 MHz on a Gemini 300 or Varian Mercury 300 spectrometer with an ASW 5 mm probe, and usually recorded at ambient temperature in a deuterated solvent, such as D 2 O, DMSO-D 6 or CDCI3 unless otherwise noted.
  • Chemical shifts values ( ⁇ ) are indicated in parts per million (ppm) with reference to tetramethylsilane (TMS) as the internal standard.
  • TMS tetramethylsilane
  • High Pressure Liquid Chromatography-Mass Spectrometry (LCMS) experiments to determine retention times (R T ) and associated mass ions are performed using one of the following methods:
  • Mass Spectra are recorded using a Micromass mass spectrometer. Generally, the method used was positive electro-spray ionization, scanning mass m/z from 100 to 1000. Liquid chromatography was performed on a Hewlett Packard 1100 Series Binary Pump &
  • ELS Evaporative Light Scattering
  • Example 3 The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(3-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 5-fluoro-2- methylbenzoyl chloride (from Alfa Aesar). MS: 396.3 (M+H).
  • Example 3 The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(3-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 5-fluoro-2- methylbenzoyl chloride (from Alfa Aesar). MS: 396.3 (M+H).
  • Example 3 Example 3
  • the title compound was prepared in a manner substantially the same as Example 1 by coupling 4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 3 -trifluoromethyl-benzoyl chloride. MS: 418.2 (M+H).
  • the title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-(S)-methyl-[l,3' (S)]bipyrrolidinyl-r-yl)-phenylamine with 5-fluoro- 2-methyl-benzoyl chloride (from Alfa Aesar).
  • LCMS: R x 2.14 minutes, MS: 396 (M+H).
  • the title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-(R)-methyl-[l,3' (R)]bipyrrolidinyl-r-yl)-phenylamine with 5-fluoro- 2-methyl-benzoyl chloride (from Alfa Aesar).
  • LCMS: R x 1.61 minutes, MS: 396 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(2S)-methyl-[l,3'(3'S)]bipyrrolidinyl-r-yl)-phenylamine with 2,3- dihydro-benzofuran-5-carbony chloride.
  • LCMS: R x 1.19 minutes, MS: 406.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 2-fluoro- benzoyl chloride. MS: 436.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 3 -pyridin-3 -yl-acryloyl chloride. MS: 377.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 2,5-Dioxo- 2,3,4,5-tetrahydro-lH-benzo[e][l,4]diazepine-8-carboxylic acid. MS: 462.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)-phenylamine with tetrahydro- furan-2-carboxylic acid. MS: 358.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 6-Chloro- imidazo[l,2-a]pyridine-2-carboxylic acid. MS: 438.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with thiophene-2- carboxylic acid. MS: 370.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-oxo-4,5,6,7- tetrahydro-benzofuran-2-carboxylic acid. MS: 422.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-isopropyl-3- sulfamoyl-benzoic acid. MS: 485.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-(lH-pyrazol-3- yl)-benzoic acid. MS: 430.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with benzofuran-5 - carboxylic acid. MS: 404.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 6-methoxy- benzofuran-2-carboxylic acid. MS: 434.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-pyridin-3-yl- lH-benzoimidazole-5-carboxylic acid. MS: 481.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 6-chloro-4-oxo- 4H-chromene-2-carboxylic acid. MS: 466.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 5-chloro-6-(2- hydroxy-ethylamino)-nicotinic acid. MS: 458.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 6-benzyloxy- methyl-nicotininic acid. MS: 485.5 (M+H).
  • the title compound is prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with thiophene-2- carboxylic acid. MS: 370.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 4-(4,6-dimethyl- pyrimidin-2-ylamino) benzoic acid. MS: 485.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 1 -acetyl-pyrrolidine -2- carboxylic acid. MS: 385.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with lH-Indole-2- carboxylic acid. MS: 403.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-hydroxy-7- methyl-[l,8]naphthyridine-3-carboxylic acid. MS: 446.5 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)-phenylamine with lH-indole- 5-carboxylic acid. MS: 403.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 4-(l-acetyl- piperidin-3-yl)-benzoic acid. MS: 489.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 4-(3,5-dimethyl- lH-pyrazol-4-yl) benzoic acid. MS: 458.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-(2-oxo- pyrrolidin-l-yl)-benzoic acid. MS: 447.5 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)-phenylamine with lH-indole- 6-carboxylic acid. MS: 403.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with imidazo-[l,2-a]pyridine-8- carboxylic acid. MS: 390.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with lH-indole-2- carboxylic acid. MS: 403.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 2-methane- sulfonyl-acetic acid. MS: 380.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[ 1 ,3'(S)]bipyrrolidinyl- 1 '-yl)-phenylamine with benzofuran-6-carboxylic acid. MS: 404.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-methane- sulfonyl-acetic acid. MS: 380.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 1-acetyl- pyrrolidine-2-carboxylic acid. MS: 399.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with lH-indole-5- carboxylic acid. MS: 403.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenylamine with 3 - methoxy-benzoyl chloride. MS: 448.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2,3-dihydro- benzo[l,4]dioxine-6-carboxylic acid. MS: 422.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)-phenylamine with 6-methyl- pyridine-2-carboxylic acid. MS: 379.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 2-methyl-lH- benzoimidazole-5-carboxylic acid. MS: 418.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 'Jbipyrrolidinyl- l'-yl)-phenylamine with 3-methane- sulfonyl-4-methyl-benzoyl chloride. MS: 456.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4,4'- biscarboxydiphenyl ether. MS: 500.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 'Jbipyrrolidinyl- l'-yl)-phenylamine with 6-morpholin-4- yl-nicotinic acid. MS: 450.5 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 5-methyl-2- phenyl-2H-[l,2,3]triazole-4-carboxylic acid. MS: 445.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-benzoyl-lH- pyrrole-2-carboxylic acid. MS: 457.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 1-isopropyl-lH- benzotriazole-5-carboxylic acid. MS: 447.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with quinoline-3 - carboxylic acid. MS: 415.3 (M+H).
  • Example 112 4-Imidazol- 1 -yl-N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 4-imidazol- 1 -yl benzoic acid. MS: 430.5 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with lH-indole-6- carboxylic acid. MS: 403.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 6-methoxy-lH- indazole-3-carboxylic acid. MS: 434.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-methanesulfonyl acetic acid. MS: 366.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 2- dimethylamino acetic acid. MS: 399.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenylamine with imidazo[l,2-a]pyridine-8-carboxylic acid. MS: 458.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-oxo-2,3- dihydro-lH-benzoimidazole-S-carboxylic acid. MS: 420.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 3 -methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 4-morpholin-4- ylmethyl-benzoyl chloride. MS: 463.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 'Jbipyrrolidinyl- l'-yl)-phenylamine with 4-(l-propoxy- ethyl)-benzoic acid. MS: 463.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with nicotinic acid. MS: 419.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-[(4,6-dimethyl- pyrimidin-2-yl)-methyl-amino]-benzoic acid. MS: 499.5 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with A- dimethylamino-benzoic acid. MS: 407.3 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 4- methanesulfonyl-benzoic acid. MS: 496.2 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with benzo[d]imidazo[2,l-b]thiazole-2-carboxylic acid. MS: 460.4 (M+H).
  • the title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 5 -methoxy- IH- indole-2-carboxylic acid. MS: 433.2 (M+H).
  • This Example demonstrates the efficacy of compounds of this invention as H3 receptor ligands.
  • the compounds of this invention have been demonstrated to displace [ H]- Methylhistamine radioligand binding to mammalian cell membranes expressing rhesus (Macacca Mulatta) H3 receptor. These compounds display rhesus H3 affinity constants (Ki) in the range of 1 ⁇ M to ⁇ 1 nM.
  • the compounds of this invention have been demonstrated by GTP ⁇ S radioligand binding assay to inhibit rhesus H3 constitutive functional activity in cell membranes. This inhibition of basal rhesus H3-mediated GTP ⁇ S radioligand binding demonstrates that the compounds of this invention find utility as inverse agonists. These compounds decreased rhesus H3 GTP ⁇ S radioligand binding by 0-40% below basal levels.
  • Rhesus H3 membranes were prepared from the FIp-In T-REx 293 Cell Line (Invitrogen) stably transfected with pcDNA5/FRT/TO (Invitrogen) containing the rhesus monkey (Macacca Mulatta) 445 amino acid H3 receptor. (Genbank #AY231164). Stably transfected cultures were amplified in tissue culture flasks by standard tissue culture methods and induced to express rhesus H3 by exposure to 500 ng/ml tetracycline (Cellgro) for 24 hours. After induction, cells were dissociated from flasks utilizing Cell Stripper (Cellgro).
  • Rhesus H3 radioligand binding assay was performed using rhesus H3 receptor membranes (prepared as described above), [3H]-Methylhistamine (Perkin Elmer) and WGA SPA beads (wheat germ agglutinin scintillation proximity assay) beads (Amersham). The assay was performed in 96-well Opti-Plates (Packard). Each reaction contained 50 ⁇ l rhesus H3 membranes (20-30 ⁇ g total protein), 50 ⁇ l WGA SPA beads (0.1 ⁇ g) and 50 ⁇ l of 83Ci/mmol [ 3 H]-Methylhistamine (final concentration 2 nM) and 50 ⁇ l of tested compound.
  • Example 2 illustrates that the stereochemistry of the compounds of this invention has an effect on the biological activity.
  • a few of the representative compounds of this invention were used in this example to show this difference in biological activity based on the stereoisomeric form. All of the compounds of this Example were tested for H3 receptor ligand activity in accordance with the procedures as set forth in Example 148. The results are tabulated in Table 2.
  • This Example illustrates selective affinity of the compounds of this invention at H3 receptors and exhibit low activity at the MCH-I receptor site.
  • Test Compounds The compounds of this invention were stored in a 96-well microtiter plates (1 ⁇ L, 10 mM, 100% DMSO). Each of the test sample was diluted with 249 ⁇ L of 100% DMSO (dilution 1 :250). The test compounds were further diluted 1 :4 (0.1% DMSO) during assay resulting in the final concentration of test compounds of this invention to be 10 ⁇ M.
  • Negative Control 40 ⁇ M of MCH-I in assay buffer with 0.4% DMSO were transferred to the dilution microtiter plates for control which resulted in final concentration of 10 ⁇ M.
  • Blank Assay buffer containing 0.4% DMSO were transferred to the dilution microtiter plates for blanks.
  • reaction mixture was removed by vacuum filtration, washed 4 x with 300 ⁇ l ice-cold washing buffer and the washing solution was removed by vacuum filtration.
  • the rubber layer at the bottom of the plate was then removed and the filters were dried over night at room temperature.
  • 25 ⁇ l of scintillation cocktail was added and the plates were sealed and, plate frames were added and incubated for 1 hour at room temperature. The radioactivity was then measured, settings 125 J standard, 30 sec/well. From this the percent inhibition of ligand binding was measured.
  • This Example illustrates the study of efficacy of the compounds of this invention in enhancing the wakefulness in animal models.
  • Cortical electrodes Small stainless steel screw electrodes of 0.9 mm in diameter were screwed into the bone over the sensorimotor cortex (1.5 mm lateral to the median suture and 1.5 mm behind the fronto-parietal suture), the visual cortex (1.5 mm lateral to the median suture and 1.5 mm in front of the parietooccipital suture) and over the cerebellum (reference electrode). Cortical electrodes were attached to a connector (Winchester, 7-lead) and fixed with dental cement to the cranium.
  • mice were placed in plexiglass cylinders (60 cm diameter) with free access to food and water.
  • the temperature of the room was kept constant (21 ⁇ 1 0 C) and lights were on from 7 a.m. to 7 p.m.
  • the rats were recorded from 10 a.m. to 4 p.m. during three consecutive days: control day (Dl), drug day (D2) and post drug day (D3).
  • Vehicle (Dl and D3) or drug (D2) were administered 15 min before the recording.
  • Activity in sensorimotor and visual cortices were recorded by comparison with the reference electrode placed over the cerebellar cortex.
  • W wakefulness
  • EoG low voltage fast electrocortical
  • SWS slow wave sleep
  • REM sleep rapid eye movement or paradoxical sleep: PS
  • REM sleep characterized by hypersynchronization of the theta rhythm in the visual area.
  • the compounds of this invention were dissolved in 0.6% MTC tween and administered by oral route (po).
  • the volume of injection was 0.5ml/100g of body weight.
  • results are expressed in minutes (one hour-period analysis) or as the percentage of the control values (100%).
  • Statistical analysis of the data was carried out using the Student's t test for paired values to determine significant variations from control values.
  • This Example further illustrates the study of efficacy of the compounds of this invention as antidepressive agents in animal models.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I), Wherein R, R1, R2, R3 and R4 are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefor.

Description

SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC
USE THEREOF
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to a series of substituted N-phenyl-bipyrrolidine carboxamides. The compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also relates to methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefor.
Description of the Art Histamine is a ubiquitous messenger molecule released from mast cells, enterochromaffin-like cells, and neurons. The physiological actions of histamine are mediated by four pharmacologically defined receptors (Hl, H2, H3 and H4). All histamine receptors exhibit seven transmembrane domains and are members of the G-protein-coupled receptor superfamily (GPCRs). The Hl receptor was the first member of the histamine receptor family to be pharmacologically defined, with the development of classical antihistamines (antagonists), such as diphenhydramine and fexofenadine. While antagonism of the Hl receptor of the immune system is commonly used for the treatment of allergic reactions, the Hl receptor is also expressed in various peripheral tissues and the central nervous system (CNS). In the brain, Hl is involved in the control of wakefulness, mood, appetite and hormone secretion.
The H2 receptor is also expressed in the CNS, where it may modulate several processes, including cognition. However, H2 receptor antagonists have primarily been developed to ameliorate gastric ulcers by inhibiting histamine -mediated gastric acid secretion by parietal cells. Classic H2 antagonists include cimetidine, ranitidine, and famotidine.
It should further be noted that H4 receptor function remains poorly defined, but may involve immune regulation and inflammatory processes.
H3 receptors have also been pharmacologically identified in the CNS, heart, lung, and stomach. The H3 receptor differs significantly from other histamine receptors, exhibiting low sequence homology (Hl : 22%, H2: 21%, H4: 35%). H3 is a presynaptic autoreceptor on histamine neurons in the brain and a presynaptic heteroreceptor in nonhistamine-containing neurons in both the central and peripheral nervous systems. In addition to histamine, H3 also modulates the release and/or synthesis of other neurotransmitters, including acetylcholine, dopamine, norepinepherin and serotonin. Of particular note, presynaptic modulation of histamine release by H3 allows significant regulation of Hl and H2 receptors in the brain. Modulating multiple neurotransmitter signaling pathways, H3 may contribute to varied physiological processes. Indeed, extensive preclinical evidence indicates that H3 plays a role in cognition, sleep-wake cycle and energy homeostasis. Modulators of H3 function may be useful in the treatment of obesity and central nervous system disorders (Schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, Parkinson's disease, depression, and epilepsy), sleep disorders (narcolepsy and insomnia), cardiovascular disorders (acute myocardial infarction), respiratory disorders (asthma), and gastrointestinal disorders. See generally, Hancock, Biochem. Pharmacol. 2006 Apr 14;71(8): 1103-13 and Esbenshade et al. MoI Interv. 2006 Apr;6(2):77-88, 59.
Recently, compounds that are somewhat structurally related to the compounds of the present invention have been disclosed to be melanin concentrating hormone (MCH) receptor antagonists, see specifically U.S. Patent 7,223,788. It should however be pointed out that there is no disclosure as to the activity of the compounds disclosed therein at the H3 receptor site.
All of the references described herein are incorporated herein by reference in their entirety. J
Accordingly, it is an object of this invention to provide a series of substituted N- phenyl-bipyrrolidine carboxamides as selective H3 receptor ligands for treatment of H3 receptor regulated CNS disorders.
It is also an object of this invention to provide processes for the preparation of the substituted N-phenyl-bipyrrolidine carboxamides as disclosed herein.
Other objects and further scope of the applicability of the present invention will become apparent from the detailed description that follows.
SUMMARY OF THE INVENTION
Surprisingly, it has now been found that the compounds of formula (I) are useful as H3 receptor antagonists and/or inverse agonists. The compounds of formula I are not specifically disclosed, nor exemplified, nor are their activity as H3 receptor antagonists/ inverse agonists suggested, in U.S. Patent 7,223,788 as mentioned hereinabove. Moreover, unexpectedly it has now been found that the compounds of formula (I) are selectively active only at H3 receptors and exhibit low activity at the MCH-I receptor site, which aspect becomes even more apparent from the detailed description that follows.
Thus in accordance with the practice of this invention there is provided a compound of formula (I):
Figure imgf000004_0001
wherein R, R1, R2 and R3 are the same or different and independently of each other chosen from hydrogen, (Ci-C4)alkyl or CF3;
R4 is selected from the group consisting of dimethylaminomethyl, methanesulfonylmethyl, phenoxymethyl, vinylbenzene, ethynylbenzene, vinylpyridine, phenyl, benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro-benzofuranyl, benzodioxolyl, oxo-chromenyl, dihydrobenzo-dioxinyl, dioxo-tetrahydro-lH-benzo[e]diazepinyl, imidazopyridinyl, benzotriazolyl, benzoimidazolyl, oxo-dihydro-benzoimidazolyl, indolyl, indazolyl, naphthyridinyl, quinolinyl, benzoimidazothiazolyl, pyridinyl, pyrimidinyl, pyrrolyl, triazolyl, thienyl, thiazolyl, tetrahydrofuranyl or pyrrolidinyl; wherein said R4 is optionally substituted one or more times with a substituent selected from halogen, hydroxy, methyl, ethyl, isopropyl, propoxyethyl, phenyl, benzoyl, methoxy, difluoromethoxy, CF3, CN, acetyl, methanesulfonyl, sulfamoyl, dimethylamino, N-formyl-methylamino, 2-hydroxyethylamino, 2-methoxyethylamido, benzyloxymethyl, carboxyphenoxy, pyrazolyl, 3,5-dimethyl-pyrazolyl, imidazolyl, triazolyl, oxazolyl, pyridinyl, oxo-dihydro-pyridinyl, pyrimidinyl-methylamino, N-acetyl-piperidinyl, morpholinyl, morpholinylmethyl or 2-oxo-pyrrolidinyl. This invention further includes various salts of the compounds of formula (I) including various enantiomers or diastereomers of compounds of formula (I). In other aspects of this invention there are also provided various pharmaceutical compositions comprising one or more compounds of formula (I) as well as their therapeutic use in alleviating various diseases which are mediated in-part and/or fully by H3 receptors.
DETAILED DESCRIPTION OF THE INVENTION The terms as used herein have the following meanings: As used herein, the expression "(Ci-C6)alkyl" includes methyl and ethyl groups, and straight-chained or branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and tert-butyl. Derived expressions such as "(C1- C4)alkoxy", "(Ci-C4)thioalkyl" "(Ci-C4)alkoxy(Ci-C4)alkyl", "hydroxy(Ci-C4)alkyl", "(C1- C4)alkylcarbonyl", "(Ci-C4)alkoxycarbonyl(Ci-C4)alkyl", "(Ci-C4)alkoxycarbonyl", "amino(Ci-C4)alkyl", "(Ci-C4)alkylamino", "(Ci-C4)alkylcarbamoyl(Ci-C4)alkyl",
"(Ci-C4)dialkylcarbamoyl(Ci-C4)alkyl" "mono- or di-(Ci-C4)alkylamino(Ci-C4)alkyl", "amino(Ci-C4)alkylcarbonyl" "diphenyl(Ci-C4)alkyl", "phenyl(Ci-C4)alkyl",
"phenylcarboyl(Ci-C4)alkyl" and "phenoxy(Ci-C4)alkyl" are to be construed accordingly.
As used herein, the expression "cycloalkyl" includes all of the known cyclic radicals. Representative examples of "cycloalkyl" include without any limitation cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. Derived expressions such as "cycloalkoxy", "cycloalkylalkyl", "cycloalkylaryl", "cycloalkylcarbonyl" are to be construed accordingly.
As used herein, the expression "(C2-C6)alkenyl" includes ethenyl and straight-chained or branched propenyl, butenyl, pentenyl and hexenyl groups. Similarly, the expression "(C2- C6)alkynyl" includes ethynyl and propynyl, and straight-chained or branched butynyl, pentynyl and hexynyl groups. As used herein the expression "(Ci-C4)acyl" shall have the same meaning as "(Ci-C6)alkanoyl", which can also be represented structurally as "R-CO-," where R is a (Ci-C3)alkyl as defined herein. Additionally, "(Ci-C3)alkylcarbonyl" shall mean same as (C1- C4)acyl. Specifically, "(Ci-C4)acyl" shall mean formyl, acetyl or ethanoyl, propanoyl, n- butanoyl, etc. Derived expressions such as "(Ci-C4)acyloxy" and "(Ci-C4)acyloxyalkyl" are to be construed accordingly.
As used herein, the expression "(Ci-C6)perfluoroalkyl" means that all of the hydrogen atoms in said alkyl group are replaced with fluorine atoms. Illustrative examples include trifluoromethyl and pentafluoroethyl, and straight-chained or branched heptafluoropropyl, nonafluorobutyl, undecafluoropentyl and tridecafluorohexyl groups. Derived expression, "(Ci-C6)perfluoroalkoxy", is to be construed accordingly.
As used herein, the expression " (C6-C io)aryl" means substituted or unsubstituted phenyl or naphthyl. Specific examples of substituted phenyl or naphthyl include o-, p-, m-tolyl, 1,2-, 1,3-, 1,4-xylyl, 1-methylnaphthyl, 2-methylnaphthyl, etc. "Substituted phenyl" or "substituted naphthyl" also include any of the possible substituents as further defined herein or one known in the art. Derived expression, "(C6-Cio)arylsulfonyl," is to be construed accordingly.
As used herein, the expression "(C6-Cio)aryl(Ci-C4)alkyl" means that the (Ce-Cio)aryl as defined herein is further attached to (Ci-C4)alkyl as defined herein. Representative examples include benzyl, phenylethyl, 2-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl and the like.
As used herein, the expression "heteroaryl" includes all of the known heteroatom containing aromatic radicals. Representative 5-membered heteroaryl radicals include furanyl, thienyl or thiophenyl, pyrrolyl, isopyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, isothiazolyl, and the like. Representative 6-membered heteroaryl radicals include pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like radicals. Representative examples of bicyclic heteroaryl radicals include, benzofuranyl, benzothiophenyl, indolyl, quinolinyl, isoquinolinyl, cinnolyl, benzimidazolyl, indazolyl, pyridofuranyl, pyridothienyl, and the like radicals. As used herein, the expression "heterocycle" includes all of the known reduced heteroatom containing cyclic radicals. Representative 5-membered heterocycle radicals include tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, 2-thiazolinyl, tetrahydrothiazolyl, tetrahydrooxazolyl, and the like. Representative 6-membered heterocycle radicals include piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and the like. Various other heterocycle radicals include, without limitation, aziridinyl, azepanyl, diazepanyl, diazabicyclo[2.2.1]hept-2-yl, and triazocanyl, and the like.
"Halogen" or "halo" means chloro, fluoro, bromo, and iodo. As used herein, "patient" means a warm blooded animal, such as for example rat, mice, dogs, cats, guinea pigs, and primates such as humans.
As used herein, the expression "pharmaceutically acceptable carrier" means a nontoxic solvent, dispersant, excipient, adjuvant, or other material which is mixed with the compound of the present invention in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to the patient. One example of such a carrier is pharmaceutically acceptable oil typically used for parenteral administration.
The term "pharmaceutically acceptable salts" as used herein means that the salts of the compounds of the present invention can be used in medicinal preparations. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfamic acid, sulfuric acid, methanesulfonic acid, 2-hydroxyethanesulfonic acid, p- toluenesulfonic acid, fumaric acid, maleic acid, hydroxymaleic acid, malic acid, ascorbic acid, succinic acid, glutaric acid, acetic acid, propionic acid, salicylic acid, cinnamic acid, 2- phenoxybenzoic acid, hydroxybenzoic acid, phenylacetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, carbonic acid or phosphoric acid. The acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate can also be formed. Also, the salts so formed may present either as mono- or di- acid salts and can exist substantially anhydrous or can be hydrated. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts, and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
As used herein, the term "prodrug" shall have the generally accepted meaning in the art. One such definition includes a pharmacologically inactive chemical entity that when metabolized or chemically transformed by a biological system such as a mammalian system is converted into a pharmacologically active substance.
The expression "stereoisomers" is a general term used for all isomers of the individual molecules that differ only in the orientation of their atoms in space. Typically it includes mirror image isomers that are usually formed due to at least one asymmetric center, (enantiomers). Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereoisomers, also certain individual molecules may exist as geometric isomers (cis/trans). Similarly, certain compounds of this invention may exist in a mixture of two or more structurally distinct forms that are in rapid equilibrium, commonly known as tautomers. Representative examples of tautomers include keto-enol tautomers, phenol-keto tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
As used herein, 'R' and 'S' are used as commonly used terms in organic chemistry to denote specific configuration of a chiral center. The term 'R (rectus) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The term 'S' (sinister) refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The priority of groups is based upon sequence rules wherein prioritization is first based on atomic number (in order of decreasing atomic number). A listing and discussion of priorities is contained in Stereochemistry of Organic Compounds, Ernest L. Eliel, Samuel H. Wilen and Lewis N. Mander, editors, Wiley-Interscience, John Wiley & Sons, Inc., New York, 1994. In addition to the (R)-(S) system, the older D-L system may also be used herein to denote absolute configuration, especially with reference to amino acids. In this system a Fischer projection formula is oriented so that the number 1 carbon of the main chain is at the top. The prefix 'D' is used to represent the absolute configuration of the isomer in which the functional (determining) group is on the right side of the carbon at the chiral center and 'L', that of the isomer in which it is on the left.
The term "solvate" as used herein means that an aggregate that consists of a solute ion or molecule with one or more solvent molecules. Similarly, a "hydrate" means that a solute ion or molecule with one or more water molecules. In a broad sense, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a few of the specific embodiments as disclosed herein, the term "substituted" means substituted with one or more substituents independently selected from the group consisting of (Ci_Ce)alkyl, (C2-Ce)alkenyl, (Ci_C6)perfluoroalkyl, phenyl, hydroxy, -CO2H, an ester, an amide, (Ci-Ce)alkoxy, (Ci-Ce)thioalkyl, (Ci-C6)perfluoroalkoxy, -NH2, Cl, Br, I, F, -NH-lower alkyl, and -N(lower alkyl)2. However, any of the other suitable substituents known to one skilled in the art can also be used in these embodiments.
"Therapeutically effective amount" means an amount of the compound which is effective in treating the named disease, disorder or condition. The term "treating" refers to:
(i) preventing a disease, disorder or condition from occurring in a patient that may be predisposed to the disease, disorder and/or condition, but has not yet been diagnosed as having it;
(ii) inhibiting the disease, disorder or condition, i.e., arresting its development; and (iii) relieving the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.
Thus, in accordance with the practice of this invention there is provided a compound of the formula I:
Figure imgf000009_0001
wherein
R, Ri, R2 and R3 are the same or different and independently of each other chosen from hydrogen, (Ci-C4)alkyl or CF3; R4 is selected from the group consisting of dimethylaminomethyl, methanesulfonylmethyl, phenoxymethyl, vinylbenzene, ethynylbenzene, vinylpyridine, phenyl, benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro-benzofuranyl, benzodioxolyl, oxo-chromenyl, dihydrobenzo-dioxinyl, dioxo-tetrahydro-lH-benzo[e]diazepinyl, imidazopyridinyl, benzotriazolyl, benzoimidazolyl, oxo-dihydro-benzoimidazolyl, indolyl, indazolyl, naphthyridinyl, quinolinyl, benzoimidazothiazolyl, pyridinyl, pyrimidinyl, pyrrolyl, triazolyl, thienyl, thiazolyl, tetrahydrofuranyl or pyrrolidinyl; wherein said R4 is optionally substituted one or more times with a substituent selected from halogen, hydroxy, methyl, ethyl, isopropyl, propoxyethyl, phenyl, benzoyl, methoxy, difluoromethoxy, CF3, CN, acetyl, methanesulfonyl, sulfamoyl, dimethylamino,
N-formyl-methylamino, 2-hydroxyethylamino, 2-methoxyethylamido, benzyloxymethyl, carboxyphenoxy, pyrazolyl, 3,5-dimethyl-pyrazolyl, imidazolyl, triazolyl, oxazolyl, pyridinyl, oxo-dihydro-pyridinyl, pyrimidinyl-methylamino,
N-acetyl-piperidinyl, morpholinyl, morpholinylmethyl or 2-oxo-pyrrolidinyl. This invention further includes various salts of the compounds of formula (I) including various enantiomers or diastereomers of compounds of formula (I). As noted hereinabove and by way of specific examples hereafter all of the salts that can be formed including pharmaceutically acceptable salts are part of this invention. As also noted hereinabove and hereafter all of the conceivable enantiomeric and diastereomeric forms of compounds of formula (I) are part of this invention.
In one of the embodiments, there is disclosed hereinbelow by way of specific examples the compounds of formula (I) of this invention wherein R is methyl; R2 is methyl or CF3; and Ri and R3 are hydrogen.
In another embodiment, there is disclosed, the compound of formula (I) wherein R is methyl; Ri is methyl or CF3; and R2 and R3 are hydrogen.
In yet another embodiment there is disclosed compounds of formula (I) of this invention wherein R4 is phenyl or phenyl substituted with one or more groups selected from fluorine, chlorine, methyl, isopropyl, propoxyethyl, CF3, CN, methoxy, difluoromethoxy, methanesulfonyl, sulfamoyl, dimethylamino, N-formyl-methylamino, carboxyphenoxy, oxo-dihydro-pyridinyl, pyrimidinyl-methylamino, pyrazolyl, 3,5-dimethyl-pyrazolyl, imidazolyl, triazolyl, oxazolyl, N-acetyl-piperidinyl, morpholinylmethyl or 2-oxo- pyrrolidinyl.
In a further embodiment of this invention there is also disclosed compounds of formula (I) wherein R4 is selected from benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro- benzofuranyl, benzodioxolyl, dihydrobenzo-dioxinyl, dioxo-tetrahydro-lH- benzo[e]diazepinyl or oxo-chromenyl, in which said R4 is optionally substituted one or more times with chlorine, methyl or methoxy. In yet another embodiment of this invention there is disclosed compounds of formula (I) wherein R4 is selected from dimethylaminomethyl, methanesulfonylmethyl, phenoxymethyl, vinylbenzene, ethynylbenzene or vinylpyridine, in which said R4 is optionally substituted one or more times with fluorine. In yet another embodiment of this invention there is provided compounds of formula
(I) wherein R4 is pyridinyl or pyrimidinyl, which is optionally substituted one or more times with chlorine, methyl, 2-hydroxyethylamino, 2-methoxyethylamido, benzyloxymethyl or morpholinyl.
In a further embodiment of this invention there is also provided compounds of formula (I) wherein R4 is selected from imidazopyridinyl, benzotriazolyl, benzoimidazolyl, oxo- dihydro-benzoimidazolyl, indolyl, indazolyl, naphthyridinyl, quinolinyl or benzoimidazothiazolyl, in which said R4 is optionally substituted one or more times with fluorine, chlorine, hydroxy, methyl, isopropyl, methoxy or pyridinyl.
In another embodiment of this invention there is provided compounds of formula (I) wherein R4 is selected from pyrrolyl, triazolyl, thienyl or thiazolyl, in which said R4 is optionally substituted one or more times with methyl, phenyl, benzoyl or pyridinyl.
In a further embodiment of this invention there is disclosed compounds of formula (I) wherein R4 is selected from tetrahydrofuranyl or pyrrolidinyl, which is optionally substituted one or more times with acetyl. It should further be noted that all of the above compounds of various embodiments of this invention may also include corresponding salts wherever possible including the pharmaceutically acceptable salts thereof.
In another aspect of this invention the compound of this invention may be represented by a specific stereoisomeric form of formula (II):
Figure imgf000011_0001
wherein R, R1, R2, R3 and R4 are as defined hereinabove.
In one aspect of the invention a few of the specific compounds encompassed by the generic scope of the invention without any limitation are enumerated as follows: N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-2-phenoxy-acetamide;
N- [2-methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-2-phenoxy-acetamide;
N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-2-phenoxy-acetamide;
N- [4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]-2-phenoxy-acetamide; 2-dimethylamino-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]- acetamide;
2-methanesulfonyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-acetamide;
2-methanesulfonyl-N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-acetamide;
2-methanesulfonyl-N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-acetamide; 2-methanesulfonyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]- acetamide;
(E)-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-3-pyridin-3-yl-acrylamide;
(E)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-3-pyridin-3-yl-acrylamide;
(E)-N-[3 -methy l-4-(2 -methyl- [ 1 ,3 ']bipyrrolidiny 1- l'-yl)-pheny 1] -3 -pyridin-3 -yl-acrylamide; (E)-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]-3-pyridin-3-yl- acrylamide;
(E)-3-(3-fluoro-phenyl)-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-acrylamide;
(E)-3-(3-fluoro-phenyl)-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]- acrylamide; 3-phenyl-propynoic acid [3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide;
2-fluoro-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
2-fluoro-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
2-fluoro-N-[2-methyl-4-(2-(2R)-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide
2-fluoro-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide; 2-fluoro-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]-benzamide;
3-fluoro-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
3-fluoro-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
3-fluoro-N-[2-methyl-4-(2-(S)-methyl-[ 1 ,3' (S)]bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide;
3-fluoro-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide; 3-fluoro-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]-benzamide;
4-fluoro-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
4-fluoro-N-[2-methyl-4-(2-(2R)-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide;
4-fluoro-N-[2-methyl-4-(2(2S)-methyl-[ 1 ,3'(3 ' S)]bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide; 5-fluoro-2-methyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
5 -fluoro-2-methyl-N- [2 -methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- l'-yl)-phenyl] -benzamide;
5-fluoro-2-methyl-N-[2-methyl-4-(2-(2S)-methyl-[ 1 ,3' (3'S)]bipyrrolidinyl- 1 '-yl)-phenyl]- benzamide; 5-fluoro-2-methyl-N-[2-methyl-4-(2(2S)-methyl-[ 1 ,3'(3 'R)]bipyrrolidinyl- 1 '-yl)-phenyl]- benzamide;
5-fluoro-2-methyl-N-[2-methyl-4-(2(2R)-methyl-[l,3'(3'S)]bipyrrolidinyl-r-yl)-phenyl]- benzamide;
5 -fluoro-2-methyl-N- [2-methyl-4-(2-(R)-methyl- [ 1 ,3 ' (R)]bipyrrolidinyl- l'-yl)-phenyl] - benzamide;
5 -fluoro-2-methyl-N- [3 -methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- l'-yl)-phenyl] -benzamide;
5-fluoro-2-methyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]- benzamide;
4-chloro-N-[4-(2-methyl-[ 1 ,3 jbipyrrolidinyl- 1 '-yl)-phenyl] -benzamide; 4-chloro-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
4-chloro-N-[2-methyl-4-(2-(S)-methyl-[ 1 ,3' (S)]bipyrrolidinyl- 1 '-yl)-phenyl] -benzamide;
4-chloro-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
3,5-dichloro-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
3,5-dichloro-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide; 3,5-dichloro-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
3 ,5 -dichloro-N- [4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- r-yl)-2-trifluoromethyl-phenyl] -benzamide;
2,4-dimethyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-l'-yl)-phenyl]-benzamide;
2,4-dimethyl-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-l'-yl)-phenyl]-benzamide;
2,4-dimethyl-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-l'-yl)-phenyl]-benzamide; 2,4-dimethyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-l'-yl)-2-trifluoromethyl-phenyl]-benzamide;
3 -methanesulfonyl-4-methyl-N-[2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenyl]- benzamide;
4-methanesulfonyl-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]- benzamide; 4-isopropyl-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-l'-yl)-phenyl]-3-sulfamoyl- benzamide;
N- [2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenyl]-4-(l -propoxy-ethyl)-benzamide;
3-methoxy-N-[4-(2-methyl-[ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenyl] -benzamide; 3-methoxy-N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide;
3 -methoxy-N-[4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]-benzamide;
4-methoxy-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide;
4-methoxy-N- [3 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide; 4-methoxy-N- [4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]-benzamide;
N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-3-trifluoromethyl-benzamide;
N- [2-methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-3-trifluoromethyl-benzamide;
N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-3-trifluoromethyl-benzamide;
4-difluoromethoxy-N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide; 4-methanesulfonyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
4-methanesulfonyl-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
4-methanesulfonyl-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
4-cyano-N- [2 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide;
4-cyano-N- [3 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide; 4-cyano-N- [4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]-benzamide;
2-dimethylamino-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
2-dimethylamino-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]- benzamide;
3-dimethylamino-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide; 3-dimethylamino-N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide;
3-dimethylamino-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]- benzamide;
4-dimethylamino-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide;
4-dimethylamino-N- [3 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide; 4-(formyl-methyl-amino)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]- benzamide;
4- {4-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylcarbamoyl]-phenoxy} -benzoic acid;
4-imidazol-l -yl-N- [2 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide; N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-4-(lH-pyrazol-3-yl)-benzamide;
4-(3,5-dimethyl-lH-pyrazol-4-yl)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl] -benzamide;
N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-4-oxazol-5-yl-benzamide; N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-4-[ 1 ,2,4]triazol-l -yl-benzamide;
4-(4,6-dimethyl-pyrimidin-2-ylamino)-N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)- phenyl] -benzamide;
4-[(4,6-dimethyl-pyrimidin-2-yl)-methyl-amino]-N-[2-methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide;
N- [2-methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-4-(6-oxo- 1 ,6-dihydro-pyridin-3- yl)-benzamide;
4-(l-acetyl-piperidin-3-yl)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]- benzamide; N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-4-morpholin-4-ylmethyl- benzamide;
N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-4-morpholin-4-ylmethyl- benzamide;
N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-4-(2-oxo-pyrrolidin- 1 -yl)- benzamide; benzo[l ,3]dioxole-5-carboxylic acid [2 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)- phenyl]-amide;
2,3-dihydro-benzo[l,4]dioxine-6-carboxylic acid [2 -methyl-4-(2 -methyl- [1,3 'Jbipyrrolidinyl-
1 '-yl)-phenyl]-amide; benzofuran-5-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]- amide; benzofuran-6-carboxylic acid [2-methyl-4-(2(S)-methyl-[ 1 ,3'(S)]bipyrrolidinyl- 1 '-yl)-phenyl]- amide;
5-methoxy-benzofuran-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ?-yl)- phenyl]-amide;
6-methoxy-benzofuran-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ?-yl)- phenyl]-amide;
2,3-dihydro-benzofuran-5-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl]-amide; 2,3-dihydro-benzofuran-5-carboxylic acid [2-methyl-4-(2(2S)-methyl-
[ 1 ,3 '(3 ' S)]bipyrrolidinyl- 1 '-yl)-phenyl]-amide;
4-oxo-4,5 ,6,7-tetrahydro-benzofuran-2-carboxylic acid [2-methyl-4-(2-methyl-
[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide; 2,5-dioxo-2,3,4,5-tetrahydro-lH-benzo[e][l,4]diazepine-8-carboxylic acid [2-methyl-4-(2- methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide;
1 -isopropyl- lH-benzotriazole-5-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '- yl)-phenyl]-amide; 6-chloro-imidazo[l,2-a]pyridine-2-carboxylic acid [2-methyl-4-(2-methyl-
[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide; imidazo[ 1 ,2-a]pyridine-8-carboxylic acid [4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]- amide; imidazo[ 1 ,2-a]pyridine-8-carboxylic acid [3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ?-yl)- phenyl]-amide; imidazo[ 1 ,2-a]pyridine-8-carboxylic acid [4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-2- trifluoromethyl-phenyl]-amide;
2-methyl-lH-benzoimidazole-5-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r- yl)-phenyl]-amide; 2-pyridin-3-yl-lH-benzoimidazole-5-carboxylic acid [2-methyl-4-(2-methyl-
[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide;
2-pyridin-2-yl-lH-benzoimidazole-5-carboxylic acid [2-methyl-4-(2-methyl-
[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide;
2-oxo-2,3-dihydro-lH-benzoimidazole-5-carboxylic acid [2-methyl-4-(2-methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide; lH-indole-2-carboxylic acid [4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide; lH-indole-2-carboxylic acid [2-methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide; lH-indole-2-carboxylic acid [3 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide;
5-methoxy-lH-indole-2-carboxylic acid [2 -methyl-4-(2 -methyl- [1,3 ']bipyrrolidinyl-l'-yl)- phenyl]-amide; lH-Indole-5-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide; lH-indole-5-carboxylic acid [2-methyl-4-(2(S)-methyl-[ 1 ,3'(S)]-bipyrrolidinyl- 1 '-yl)-phenyl]- amide; lH-indole-6-carboxylic acid [2-methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide; lH-indole-6-carboxylic acid [2-methyl-4-(2(S)-methyl-[l,3'(S)]-bipyrrolidinyl-r-yl)-phenyl]- amide; β-methoxy-lH-indazole-S-carboxylic acid [2-methyl-4-(2-methyl-[l ,3']bipyrrolidinyl-l '-yl)- phenyl]-amide; quinoline-3-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide; β-fluoro-l-methyl-quinoline-S-carboxylic acid [2 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '- yl)-phenyl]-amide;
[ 1 ,6]naphthyridine-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ?-yl)- phenyl]-amide;
4-hydroxy-7-methyl-[ 1 ,8]naphthyridine-3-carboxylic acid [2-methyl-4-(2-methyl-
[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide;
6-chloro-4-oxo-4H-chromene-2-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r- yl)-phenyl]-amide; 6-methyl-4-oxo-4H-chromene-2-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-
1 '-yl)-phenyl]-amide; benzo[d]imidazo[2, 1 -b]thiazole-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl-
1 '-yl)-phenyl]-amide;
N- [4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -nicotinamide; N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-nicotinamide;
N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-nicotinamide;
N- [4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]-nicotinamide;
6-methyl-pyridine-2-carboxylic acid [2-methyl-4-(2(S)-methyl-[ 1 ,3 '(S)]bipyrrolidinyl- 1 ?-yl)- phenyl]-amide; 5-chloro-6-(2-hydroxy-ethylamino)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl] -nicotinamide;
6-benzyloxymethyl-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-nicotinamide; pyridine-2,5-dicarboxylic acid 2-[(2-methoxy-ethyl)-amide] 5-{[2-methyl-4-(2-methyl-
[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide} ; N- [2-methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-6-morpholin-4-yl-nicotinamide;
4-benzoyl- 1 H-pyrrole-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ?-yl)- phenyl]-amide; thiophene-2-carboxylic acid [4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -amide; thiophene-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -amide; thiophene-2-carboxylic acid [3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide;
2-pyridin-3-yl-thiazole-4-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl]-amide; 2-pyridin-4-yl-thiazole-4-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3 'Jbipyrrolidinyl- 1 ?-yl)- phenyl]-amide;
5-methyl-2-phenyl-2H-[l ,2,3]triazole-4-carboxylic acid [2-methyl-4-(2-methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide; tetrahydro-furan-2-carboxylic acid [2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)- phenyl]-amide; l-acetyl-pyrrolidine-2-carboxylic acid [4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide; l-acetyl-pyrrolidine-2-carboxylic acid [3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl]-amide; and l-acetyl-pyrrolidine-2-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl]-amide;
Again all of the conceivable salts of the above noted compounds including the pharmaceutically acceptable salts are part of this invention.
The compounds of this invention can be synthesized by any of the procedures known to one skilled in the art. Specifically, several of the starting materials used in the preparation of the compounds of this invention are known or are themselves commercially available. The compounds of this invention and several of the precursor compounds may also be prepared by methods used to prepare similar compounds as reported in the literature and as further described herein. For instance, as stated hereinabove a few of the structurally similar compounds have been disclosed in U. S. Patent No. 7,223,788. Also, see R. C. Larock, "Comprehensive Organic Transformations," VCH publishers, 1989.
It is also well known that in various organic reactions it may be necessary to protect reactive functional groups, such as for example, amino groups, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice and known to one of skilled in the art, for example, see T. W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, Inc., 1991. For example, suitable amine protecting groups include without any limitation sulfonyl (e.g., tosyl), acyl (e.g., benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g., benzyl), which may be removed subsequently by hydrolysis or hydrogenation as appropriate. Other suitable amine protecting groups include trifluoroacetyl [-C(=O)CF3] which may be removed by base catalyzed hydrolysis, or a solid phase resin bound benzyl group, such as a Merrifϊeld resin bound 2,6-dimethoxybenzyl group (Ellman linker) or a 2,6-dimethoxy-4-[2- (polystyrylmethoxy)ethoxy]benzyl, which may be removed by acid catalyzed hydrolysis, for example with TFA.
More specifically, the compounds disclosed herein and various precursors used therefor can be synthesized according to the following procedures of Schemes 1 - 4, wherein R, R1, R2, R3 and R4 are as defined for Formula I unless otherwise indicated.
For instance, Scheme 1 illustrates the preparation of the intermediate [1, 3']- pyrrolidinyl-pyrrolidine of formula (4), wherein R is as defined herein. First, in step 1, Scheme 1, suitably protected (for example tert-butyloxycarbonyl (boc)) pyrrolidinone of formula (1) is condensed with a desired substituted pyrrolidine of formula (2) by any of the known reductive amination procedures to from an intermediate of formula (3). For instance, such condensation reactions are generally carried out in the presence of reducing agents such as triacetoxyborohydride in an inert atmosphere, such as nitrogen atmosphere. The reaction can be carried out either at sub-ambient, ambient or super-ambient reaction temperatures and pressures. Typically, such reactions are carried out at room temperature at atmospheric pressure of nitrogen. The reaction mixture is then worked-up using procedures known to one skilled in the art to isolate the intermediate of formula (3).
In step 2, Scheme 1, the intermediate (3) is then de-protected to form the desired [1, 3']-pyrrolidinyl-pyrrolidine of formula (4). Such deprotection reactions are generally carried out under acidic conditions, for example, in the presence of hydrochloric acid at sub-ambient to ambient temperatures, for example in the temperature range of about -100C to room temperature. However, other suitable reaction temperatures can also be used depending upon the nature of the intermediate of formula (3).
Scheme 1
Figure imgf000019_0001
Scheme 2 illustrates preparation of enantiomerically pure isomers of the
[l,3']-pyrrolidinyl-pyrrolidine of formula (9), wherein R is as defined herein. In step 1, Scheme 2, suitably protected (for example boc) pyrrolidine alcohol of formula (5) is treated with p-toluene sulfonyl chloride to form intermediate of formula (6). This reaction can be carried out using any of the procedures known to one skilled in the art, such as for example carrying out the reaction in the presence of a suitable base such as triethylamine and DMAP in a suitable organic solvent, preferably an aprotic solvent such as dichloromethane at sub- ambient or ambient temperature conditions.
In step 2, Scheme 2, the intermediate of formula (6) is condensed with a desired pyrrolidine of formula (7). Again, such condensation reactions can be carried out using any of the procedures known to one skilled in the art in order to obtain the intermediate of formula (8). Typically, such condensation reactions are carried out in the presence of a base such as potassium carbonate in the presence of solvents such as acetonitrile at ambient to super- ambient temperature conditions.
In step 3, Scheme 2, the intermediate of formula (8) is then reacted with an acid, such as hydrochloric acid in a suitable solvent, such as dioxane, to form the desired stereospecific isomer of [l,3']-pyrrolidinyl-pyrrolidine intermediate of formula (9). It has now been found that the intermediates of formula (9) can be readily formed in accordance with the process of this invention with high enantiomeric purity, specific details of which are provided hereinbelow by way of various examples. In general, the enantiomeric purity can be determined by chiral HPLC. Scheme 2
Figure imgf000020_0001
Scheme 3 illustrates the preparation of amino-phenyl-pyrrolidinyl-pyrrolidine intermediate of formula (12), wherein R, Ri and R2 are as defined herein. In step 1, Scheme
3, suitably substituted nitrobenzene of formula (10), wherein X is a suitable leaving group, such as Cl, F, Br, or triflate (OTf) is condensed with the [l,3']-pyrrolidinyl-pyrrolidine of formula (4) in order to form an intermediate of formula (11). Such condensation reactions can again be carried out using any of the procedures known to one skilled in the art. For example, such condensation reaction can be carried out in a polar solvent such as DMSO in the presence of a base such as potassium carbonate at ambient to super-ambient temperature conditions.
In step 2, Scheme 3, intermediate of formula (11) is reduced by hydrogenation or other known chemical methods, such as using tin dichloride in hydrochloric acid, to form the key intermediate (12).
Scheme 3
Figure imgf000021_0001
Scheme 4 illustrates the preparation of compounds of formula (I) of this invention using either Method A or Method B depending upon the availability of desired carboxylic acid of formula R4-CO2H either in the form of the acid itself or its acid chloride, wherein R, R1, R2 and R4 are as described herein and R3 is hydrogen.
In Method A, Scheme 4 the acid chloride of formula (13) can be reacted with the intermediate (12) using any of the conditions known to one skilled in the art. Typically, such conditions include without any limitations reaction of the acid chloride with the intermediate of formula (12) in a suitable organic solvent such as for example dichloromethane in the presence of a suitable base such as pyridine. Such reactions are generally carried out at sub- ambient temperature conditions, for example around 00C, however ambient to super-ambient temperature conditions may also be suitable in certain situations depending upon the nature of the acid chloride and the intermediate (12).
Similarly, in Method B, Scheme 4, the carboxylic acid of formula (14) can be reacted with the intermediate of formula (12) under various reaction conditions known to one skilled in the art. For instance, the acid of formula (14) is reacted with intermediate of formula (12) at sub-ambient temperature conditions in the presence of suitable reagents such as for example a mixture of N-methylmorpholine, 1-hydroxybenzotriazole and EDC. Scheme 4
Figure imgf000022_0001
As already noted hereinabove, the compounds of this invention can readily be converted into salts. More particularly, the compounds of the present invention are basic, and as such compounds of this invention are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof. Acid addition salts may be a more convenient form for use; and, in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compound is preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures.
In another aspect of this embodiment, a specific disease, a disorder or a condition that can be treated with the compound of this invention include, without any limitation the following: sleep-related disorders (specific examples include without any limitation narcolepsy, circadian rhythm sleep disorders, obstructive sleep apnea, periodic limb movement and restless leg syndrome, excessive sleepiness and drowsiness due to medication side-effect, etc.), neurological disorders (specific examples that may be enumerated include but not limited to dementia, Alzheimer's disease, multiple sclerosis, epilepsy and neuropathic pain), neuropsychological and cognitive disorders (a few of the specific examples include without any limitation include schizophrenia, attention deficit/hyperactivity disorder, Alzheimer's disease, depression, seasonal affective disorder, and cognitive impairment).
As described hereinbelow by way of specific examples, the compounds of formula (I) bind to the H3 receptors and demonstrate inverse agonism versus H3 functional activity. Therefore, the compounds of this invention may have utility in the treatment of diseases or conditions ameliorated with H3 receptor ligands. More specifically, the compounds of the present invention are H3 receptor ligands that modulate function of the H3 receptor by antagonizing the activity of the receptor. Further, the compounds of this invention may be inverse agonists that inhibit the basal activity of the receptor or they may be antagonists that completely block the action of receptor-activating agonists. Additionally, the compounds of this invention may also be partial agonists that partially block or partially activate the H3 receptor or they may be agonists that activate the receptor. Thus the compounds of this invention may act differentially as antagonists, inverse agonists and/or partial agonists depending on functional output, histamine tone and or tissue context. Accordingly, the differential activities of these compounds may allow for utility to ameliorate multiple disease states as specifically enumerated above.
Thus in one aspect of this invention there is provided a method of treating a disease in a patient, said disease selected from the group consisting of sleep related disorder, dementia, Alzheimer's disease, multiple sclerosis, cognitive disorder, attention deficit hyperactivity disorder and depression, comprising administering to said patient a therapeutically effective amount of a compound of formula (I).
One of skill in the art readily appreciates that the pathologies and disease states expressly stated herein are not intended to be limiting rather to illustrate the efficacy of the compounds of the present invention. Thus it is to be understood that the compounds of this invention may be used to treat any disease caused by the effects of H3 receptors. That is, as noted above, the compounds of the present invention are modulators of H3 receptors and may be effectively administered to ameliorate any disease state which is mediated all or in part by H3 receptors.
All of the various embodiments of the compounds of this invention as disclosed herein can be used in the method of treating various disease states as described herein. As stated herein, the compounds used in the method of this invention are capable of inhibiting the effects of H3 receptor and thereby alleviating the effects and/or conditions caused due to the activity of H3. In another embodiment of the method of this invention, the compounds of this invention can be administered by any of the methods known in the art. Specifically, the compounds of this invention can be administered by oral, intramuscular, subcutaneous, rectal, intratracheal, intranasal, intraperitoneal or topical route. Finally, in yet another embodiment of this invention, there is also provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I), including enantiomers, stereoisomers, and tautomers of said compound and pharmaceutically acceptable salts, solvates or derivatives thereof, with said compound having the general structure shown in formula I as described herein. As described herein, the pharmaceutical compositions of this invention feature H3 inhibitory activity and thus are useful in treating any disease, condition or a disorder caused due to the effects of H3 in a patient. Again, as described above, all of the preferred embodiments of the compounds of this invention as disclosed herein can be used in preparing the pharmaceutical compositions as described herein. Preferably the pharmaceutical compositions of this invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the compositions may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. An erodible polymer containing the active ingredient may be envisaged. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Flavored unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
The pharmaceutical compositions of this invention can be administered by any of the methods known in the art. In general, the pharmaceutical compositions of this invention can be administered by oral, intramuscular, subcutaneous, rectal, intratracheal, intranasal, intraperitoneal or topical route. The preferred administrations of the pharmaceutical composition of this invention are by oral and intranasal routes. Any of the known methods to administer pharmaceutical compositions by an oral or an intranasal route can be used to administer the composition of this invention. In the treatment of various disease states as described herein, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 20 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.
This invention is further illustrated by the following examples which are provided for illustration purposes and in no way limit the scope of the present invention.
Examples (General)
As used in the examples and preparations that follow, the terms used therein shall have the meanings indicated: "kg" refers to kilograms, "g" refers to grams, "mg" refers to milligrams, "μg" refers to micrograms, "pg" refers to picograms, "Ib" refers to pounds, "oz" refers to ounces, "mol" refers to moles, "mmol" refers to millimoles, "μmole" refers to micromoles, "nmole" refers to nanomoles, "L" refers to liters, "mL" or "ml" refers to milliliters, "μL" refers to microliters, "gal" refers to gallons, "0C" refers to degrees Celsius, "Rf " refers to retention factor, "mp" or "m.p." refers to melting point, "dec" refers to decomposition, "bp" or "b.p." refers to boiling point, "mm of Hg" refers to pressure in millimeters of mercury, "cm" refers to centimeters, "nm" refers to nanometers, "abs." refers to absolute, "cone." refers to concentrated, "c" refers to concentration in g/mL, "DMSO" refers to dimethyl sulfoxide, "DMF" refers to N,N-dimethylformamide, "CDI" refers to 1,1'- carbonyldϋmidazole, "DCM" or "CH2Cl2" refers to dichloromethane, "DCE" refers to 1,2- dichloroethane, "HCl" refers to hydrochloric acid, "EtOAc" refers to ethyl acetate, "PBS" refers to Phosphate Buffered Saline, "IBMX" refers to 3-isobutyl-l-methylxanthine, "PEG" refers to polyethylene glycol, "MeOH" refers to methanol, "MeNH2" refers to methyl amine, "N2" refers to nitrogen gas, "iPrOH" refers to isopropyl alcohol, "Et2O" refers to ethyl ether, "LAH" refers to lithium aluminum hydride, "heptane" refers to n-heptane, "HMBA-AM" resin refers to 4-hydroxymethylbenzoic acid amino methyl resin, "PdCl2(dppf)2" refers to 1 , 1 '-bis(diphenylphosphino)ferrocene-palladium (II) dichloride DCM complex, "HBTU" refers to 2-(lH-benzotriazol-lyl)-l,l,3,3-tetramethyluronium hexafluorophosphate, "DIEA" refers to diisopropylethylamine, "CsF" refers to cesium fluoride, "MeI" refers to methyl iodide, "AcN," "MeCN" or "CH3CN"refers to acetonitrile, "TFA" refers to trifluoroacetic acid, "THF" refers to tetrahydrofuran, "NMP" refers to l-methyl-2-pyrrolidinone, "H2O" refers to water, "BOC" refers to t-butyloxycarbonyl, "brine" refers to a saturated aqueous sodium chloride solution, "M" refers to molar, "mM" refers to millimolar, "μM" refers to micromolar, "nM" refers to nanomolar, "N" refers to normal, "TLC" refers to thin layer chromatography, "HPLC" refers to high performance liquid chromatography, "HRMS" refers to high resolution mass spectrum, "L.O.D." refers to loss on drying, "μCi" refers to microcuries, "i.p." refers to intraperitoneally, "i.v." refers to intravenously, anhyd = anhydrous; aq = aqueous; min = minute; hr = hour; d = day; sat. = saturated; s = singlet, d = doublet; t = triplet; q = quartet; m = multiplet; dd = doublet of doublets; br = broad; LC = liquid chromatograph; MS = mass spectrograph; ESI/MS = electrospray ionization/mass spectrograph; RT = retention time; M = molecular ion, "~" = approximately. Reactions generally are run under a nitrogen atmosphere. Solvents are dried over magnesium sulfate and are evaporated under vacuum on a rotary evaporator. TLC analyses are performed with EM Science silica gel 60 F254 plates with visualization by UV irradiation.
Flash chromatography is performed using Alltech prepacked silica gel cartridges. The 1H NMR spectra are run at 300 MHz on a Gemini 300 or Varian Mercury 300 spectrometer with an ASW 5 mm probe, and usually recorded at ambient temperature in a deuterated solvent, such as D2O, DMSO-D6 or CDCI3 unless otherwise noted. Chemical shifts values (δ) are indicated in parts per million (ppm) with reference to tetramethylsilane (TMS) as the internal standard. High Pressure Liquid Chromatography-Mass Spectrometry (LCMS) experiments to determine retention times (RT) and associated mass ions are performed using one of the following methods:
Mass Spectra (MS) are recorded using a Micromass mass spectrometer. Generally, the method used was positive electro-spray ionization, scanning mass m/z from 100 to 1000. Liquid chromatography was performed on a Hewlett Packard 1100 Series Binary Pump &
Degasser; Auxiliary detectors used were: Hewlett Packard 1100 Series UV detector, wavelength = 220 nm and Sedere SEDEX 75 Evaporative Light Scattering (ELS) detector temperature = 460C, N2 pressure = 4 bar.
LCT: Grad (AcN+0.05% TFA):(H2O+0.05% TFA) = 5:95 (0 min) to 95:5 (2.5 min) to 95:5 (3 min). Column: YMC Jsphere 33x2 4 μM, 1 ml/min
MUX: Column: YMC Jsphere 33x2, 1 ml/min
Grad (AcN+0.05% TFA):(H2O+0.05% TFA) = 5:95 (0 min) to 95:5 (3.4 min) to 95:5 (4.4 min).
LCT2: YMC Jsphere 33x2 4 μM, (AcN+0.05%TFA):(H2O+0.05%TFA) = 5:95 (0 min) to 95:5 (3.4 min) to 95:5 (4.4 min)
QU: YMC Jsphere 33x2 lml/min, (AcN+0.08% formic acid):(H2O+0.1% formic acid) = 5:95
(0 min) to 95:5 (2.5min) to 95:5 (3.0min)
The following examples describe the procedures used for the preparation of various starting materials employed in the preparation of the compounds of this invention. INTERMEDIATES
Intermediate (i) 2-Methyl-[l,3']bipyrrolidinyl-l'-carboxylic acid tert-butyl ester
Figure imgf000028_0001
To a solution of N-BOC-3-pyrrolidinone (4.22 g, 22.9 mmol) and 2-methylpyrrolidine
(1.95 g, 22.9 mmol) (HCl salt was made by addition of 22.9 mL of 1 M HCl in ether into the
DCM solution of 2-methylpyrroline, then evaporated) in DCE (60 mL) was added powdered sodium triacetoxyborohydride slowly under N2 at r.t. The yellowish milky solution was stirred at r.t. overnight. LC/MS - m/z 255 and 199 ([M+H]+ and [[M+H]-tBu]+).
The reaction was quenched with aq. NaHCO3 solution. The two layers were separated, and the aqueous layer was extracted with DCM (20 mLx2). The combined DCM extracts were washed with sodium bicarbonate (10 mL), and brine (5 mLx2), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column, eluted with DCM and 7.5% MeOH in DCM to get the title compound as a liquid 5.50 g (yield: 94%). MS: 255 (M+H)+; TLC: 0.5 (10% MeOH in DCM).
Intermediate (ii) 2-Methyl-[ 1 ,3']bipyrrolidinyl hydrochloride
Figure imgf000028_0002
2-Methyl-[l,3']bipyrrolidinyl-l'-carboxylic acid tert-butyl ester (Intermediate (i) obtained above, 5.50 g, 21.62 mmol) was treated with 20 mL of 4 M HCl in dioxane at O0C. The solution was stirred under nitrogen at r.t. overnight. TLC (10% MeOH in DCM) did not detect the starting material. N2 was passed through the solution with stirring. The outlet was passed though KOH solution to absorb HCl for 30 min. The solvent was removed by evaporation to dryness to get the title compound as a hygroscopic gummy material, 5.3 g (-100 %). This material was used without further purification in subsequent steps as illustrated below. LCMS: Rx = 0.35 minutes, MS: 155 (M+H)+. 1U NMR (D2O, 300MHz): 4.30 (m), 3.85 (m), 3.76 (s), 3.5 (m), 3.46 (m), 3.32 (m), 2.66 (m), 2.28 (m), 2.10 (m), 1.46 (bs).
Intermediate (iii) 2-Methyl- 1'-(3 -methyl-4-nitro-phenyl)- [ 1 ,3 'Jbipyrrolidinyl
Figure imgf000029_0001
2-Methyl-[l,3']bipyrrolidinyl hydrochloride (Intermediate (ii) obtained above, 5.3 g, 21.6 mmol, 1.12 equiv.) was dissolved in anhydrous DMSO (30 mL). To this solution was added 5-fluoro-2-nitrotoluene (3.00 g, 18.78 mmol, 1 equiv.), followed by powdered potassium carbonate (8.9 g, 65 mmol). The suspension was heated on an oil bath to 850C for 4h when the starting material was consumed as determined by TLC (5% MeOH in DCM) and LC/MS. To the suspension were added 20 mL of water and 50 mL of DCM. The two layers were separated, and the aqueous layer was extracted with DCM (20 mLx2). The combined DCM extracts were washed with sodium bicarbonate (20 mL), and brine (15 mLx2), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column, eluted with 5% MeOH in DCM to get the title compound as a yellow solid after drying, 5.47 g (100%). MS: 290 (M+H+).
1H NMR (300 MHz, CDCl3): 8.10 (d, 9Hz, IH), 6.36 (bd, 9 Hz, IH), 6.28 (bs, IH), 3.4-3.2 (m, 5H), 3.00-2.78 (m, 2H), 2.64 (s, 3H), 1.7-2.2 (m, 6H), 1.5 (m, IH), 1.06 (m, 3H). Intermediate (iv)
4-(2-Methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenylamine
Figure imgf000029_0002
A solution of 2-methyl-r-(3-methyl-4-nitro-phenyl)-[l,3']bipyrrolidinyl (Intermediate
(iii) obtained above, 2.23 g, 7.7 mmol) in MeOH was de-aerated and nitrogen was introduced. To this solution was added Pd-C (10%). This mixture was stirred under H2 atmosphere at r.t. for 8h. TLC (10% MeOH in DCM) and LC/MS showed the reaction was complete. The mixture was passed through a Celite pad, rinsed with methanol. The filtrate was concentrated to dryness, and further dried under high vacuum to yield a reddish brown liquid after drying under high vacuum to obtain the title compound as a gummy black liquid, 1.73 g (86%). This material was used in the next step without further purification and storage. MS: 260 (M+H+).
Intermediate (v) 2-(2R)-Methyl-[ 1 ,3']bipyrrolidinyl hydrochloride
Figure imgf000030_0001
To a solution of N-BOC-3-pyrrolidinone (1.26 g, 6.83 mmol) and 2-(R)- methylpyrroline (0.83 g, 6.83 mmol) in DCE (20 mL) was added powdered sodium triacetoxyborohydride slowly under N2 at r.t. The yellowish milky solution was stirred at r.t. overnight. LC/MS showed m/z 255 and 199 (base peak and M-tBu peak).
The reaction was quenched with aqueous NaHCO3 solution. The two layers were separated, and the aqueous layer was extracted with DCM (10 mLx2). The combined DCM extracts were washed with sodium bicarbonate (10 mL), and brine (5 mLx2), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column, eluted with DCM and 7.5% MeOH in DCM to get a liquid, 1.29 g (yield:
74%). This thick liquid as obtained above (1.29g, 5.08 mmol) was treated with 16 mL of 4M
HCl in dioxane at O0C. The solution was stirred under nitrogen at r.t. overnight. TLC (10% MeOH in DCM) did not detect the starting material.
N2 was passed through the solution with stirring. The outlet was passed though KOH solution to absorb HCl for 30 min. The solvent was removed by evaporation to dryness to get a hygroscopic gum (HCl salt and hydrate, exact composition unknown), 1.32g (-100 %). This material was used without further purification in subsequent steps as described below. LCMS: Rx = 0.35 minutes, MS: 155 (M+H).
Intermediate (vi) 2-(2R)-Methyl-r-(3-methyl-4-nitro-phenyl)-[l,3']bipyrrolidinyl
Figure imgf000031_0001
5-Fluoro-2-nitrotoluene (1.55g, 10 mmol) was dissolved in anhydrous DMSO. To this solution was added 2-(2R)-methyl-[l,3']bipyrrolidinyl hydrochloride (2.30 g, 15 mmol), followed by powdered potassium carbonate. The suspension was heated on an oil bath to 850C for 3h when the starting material was consumed as determined by TLC (5% MeOH/DCM) and LC/MS. To the suspension were added 20 mL of water and 50 mL of DCM. The two layers were separated, and the aqueous layer was extracted with DCM (20 mLx2). The combined DCM extracts were washed with sodium bicarbonate (20 mL), and brine (15 mLx2), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column, eluted with 5% MeOH in DCM to get the title compound as a yellow solid after drying, 2.70 g (93%). MS: 290 (M+ 1). 1H NMR (CDCl3, 300MHz): 8.10 (d, 9Hz,), 6.36 (bd, 9 Hz), 6.28 (bs)3.4-3.2 (m), 3.00-2.78 (m), 2.64 (s), 1.7-2.2 (m)1.5 (m), 1.06 (d, 6.6Hz), 1.14 (d, 6.6 Hz).
Intermediate (vii) 2-Methyl-4-(2-(2R)-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine
Figure imgf000031_0002
A solution of 2-(2R)-methyl-r-(3-methyl-4-nitro-phenyl)-[l,3']bipyrrolidinyl (2 g, 6.9 mmol) in MeOH (15 mL) was de-aerated and nitrogen was introduced. To this solution was added Pd-C (10%, 0.2Og). The nitrogen was replaced with hydrogen and the mixture was stirred under H2 atmosphere at r.t. overnight. TLC (10% MeOH in DCM) and LC/MS showed the reaction was complete. The mixture was passed through a celite pad, rinsed with methanol. The filtrate was concentrated to dryness, and further dried under high vacuum to yield the title compound as a reddish brown liquid after drying under high vacuum, 2.02g (100% yield). This material is used in the next step without further purification. MS: 260 (M+H+). Intermediate (viii) 2-(2S)-Methyl-[l ,3']bipyrrolidinyl hydrochloride
Figure imgf000032_0001
The title compound was prepared in a manner substantially the same as intermediate (v) by condensing N-BOC-3-pyrrolidinone (1.26 g, 6.83 mmol) and 2-(S)-methylpyrroline, followed by de-protection with hydrochloride in dioxane. LCMS: Rx = 0.36 minutes, MS: 155 (M+H).
1H NMR (CDCl3, 300MHz): 4.16 (m), 3.77 (m), 3.61 (m), 3.13, (m) 3.31 (m), 2.53 (m), 2.41 (m) 1.98 (m), 1.67 (m), 1.31 (m). Intermediate (ix)
3-(3R)-(Toluene-4-sulfonyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester
Figure imgf000032_0002
A round-bottomed flask was charged with p-toluenesulfonyl chloride (16.01 g, 83.98 mmol, 1.5 equiv.) and 150 ml of anhydrous DCM. The solution was cooled to an ice-water bath and evacuated and purged with nitrogen. To this solution was added a solution of (3R)- (-)-N-BOC-3-hydroxypyrrolidine (purchased from Aldrich) (10.47 g, 55.99 mmol) in 50 mL of DCM, followed by DMAP (0.66 g) and triethylamine (16.2 mL). The solution was stirred under nitrogen overnight from O0C to rt. TLC (5 % MeOH in DCM) showed the completion of the reaction. The reaction was quenched by addition of polymer-supported amine (8 g), stirred 30 min. 100 mL of DCM was added. The organic layer was washed with H3PO4 (IM, 2 x 5OmL), followed by NaHCO3 (50 mL), brine (50 mL), dried (K2CO3), filtered through a silica gel pad, and concentrated to obtain the title compound as a liquid, 15.82 g (82.8 %). MS: 363 (M+Na+); TLC (DCM) Rf= 0.3. 1H NMR (CDCl3, 300MHz): 7.80 (d, 9.0Hz, 2H), 7.35 (d, 7.8Hz, 2H), 5.04 (bs, IH), 3.45 (m, 4H), 2.46 (bs, 3H), 2.05 (m, 2H), 1.43 (s, 9H). Intermediate (x) 2-(2S)-Methyl-[l,3'(3'S)]bipyrrolidinyl-r-carboxylic acid tert-butyl ester
Figure imgf000033_0001
3-(3R)-(Toluene-4-sulfonyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester (Intermediate (ix) obtained above, 15.82 g, 46.4 mmol, 1 equiv.) and S-(+)-2-methyl- piperindine (obtained from Advanced Asymmetries), (7.88 g, 92.79 mmol, 2 equiv.) were dissolved in anhydrous CH3CN ( 150 mL). To this colorless solution was added powdered
K2CO3 (powder, 325 mess, 98+%, 14.1 Ig, 102.08 mmol, 2.2 equiv.) at r.t. The suspension was heated in an oil bath maintained at 8O0C for 24h. TLC (3% MeOH in DCM for starting material (SM) and 7.5% MeOH in DCM for product) showed that the SM was consumed almost completely. LC/MS showed very little amount of SM at m/z 363, and the product at
255.
The suspension was concentrated to dryness. The residue was taken in water (25 mL) and DCM (80 mL). The two layers were separated, and the aqueous layer was extracted with DCM (20 mL x 2). The combined DCM extracts were washed with sodium bicarbonate (25 mL), and brine (25 mL), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column, eluted with MeOH in DCM (0 to 7.5 %) to get the title compound as a gummy material, 7.91 g (67%). LCMS: Rx = 1.27 minutes, MS: 255 (M+H). 1H NMR (300 MHz, CDCl3): 3.15 (m, 2H), 3.3 (m, 3H), 2.97 (m, IH), 2.71 (m, IH), 2.47 (m, IH), 1.98 (m, 2H), 1.96-1.67 (m, 4H), 1.46 (s, 9H), 1.06 (d, 6.2Hz, 3H).
Intermediate (xi) 2-(2R)-Methyl-[l,3'(3'S)]bipyrrolidinyl-l'-carboxylic acid tert-butyl ester
Figure imgf000034_0001
The title compound was prepared in a manner substantially the same as intermediate (x) by condensing 3-(3R)-(toluene-4-sulfonyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester (Intermediate (ix) obtained above and R-(-)-2-methylpiperindine (obtained from Advanced Asymmetries). LCMS: Rx = 1.05 minutes, MS: 255 (M+H). 1H NMR (300 MHz, CDC13): 3.30 (m, IH), 3.14 (bs, 2H), 2.91 (m, IH), 2.75 (m, IH), 2.51 (m, IH), 2.07-1.69 (m, 6H), 1.46 (s, 9H), 1.10 (d, 6.0Hz, 3H).
Intermediate (xii) 3-(3S)-(Toluene-4-sulfonyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester
Figure imgf000034_0002
A round bottomed flask was charged with 80 mL of anhydrous DCM. The solvent was evacuated and purged with nitrogen. To this solvent was added (3S)-l-BOC-3- pyrrolidinol (obtained from Astatech), (16.32 g, 33.8 mmol), DMAP (0.4g). The solution was cooled to an ice-water bath. To this cold solution was added a solution of p-toluene-sulfonyl chloride (9.67 g, 50.87 mmol, 1.5 equiv.) in 20 mL of DCM. The ice-water bath was removed and the solution was stirred under nitrogen overnight. TLC (5% MeOH in DCM for SM, 12 visualization; DCM for product, UV) showed the completion of the reaction. The reaction was quenched by addition of polymer-supported amine (4.5 g), stirred 30 min. 50 mL of DCM was added and filtered. The filtration pad was washed with DCM. The organic was washed with H3PO4 (IM, 2 x 5OmL), followed by NaHCO3 (50 mL, brine (50 mL), dried (K2CO3), filtered and concentrated to a liquid. This was purified on a HO g silica gel column on Analogix using 0-2% MeOH in DCM to obtain pure product, 8.82 g (77% yield). TLC (DCM) Rf = 0.3. LC: Rt = 3.55 min, 100% pure based on total ion, MS: 363 (M+Na); 342, 327, 286 (base).
1H NMR (300MHz, CDCl3): 7.81 (d, 8.7Hz, 2H), 7.37 (d, 8.7Hz, 2H), 5.04 (bs, IH), 3.45 (m, 4H), 2.46 (s, 3H), 1.44 (s, 9H). Intermediate (xiii)
2-(2S)-Methyl-[l,3'(3'R)]bipyrrolidinyl-l'-carboxylic acid tert-butyl ester
Figure imgf000035_0001
3-(3S)-(Toluene-4-sulfonyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester (Intermediate (xii) obtained above) (6.82 g, 19.97 mmol, 1 equiv. ) and S-(+)-2-methyl- piperindine (obtained from Advanced Asymmetries), (3.40 g, 40 mmol, 2 equiv.) were dissolved in anhydrous CH3CN (65 mL). To this colorless solution was added powder K2CO3 (powder, 325 mess, 98+%, 6.1Og, 44.2 mmol, 2.2 equiv.) at r.t. The suspension was heated with stirring under nitrogen over an oil bath maintained at 8O0C for 24h. TLC (3% MeOH in DCM for SM, 7.5% MeOH in DCM for product) showed the SM was consumed almost completely. LC/MS showed very little amount of SM at m/z 363.
The suspension was concentrated to dryness. The residue was taken in water (25mL) and DCM (80 mL). The two layers were separated, and the aqueous layer was extracted with DCM (20 mLx2). The combined DCM extracts were washed with sodium bicarbonate (25 mL), and brine (25 mL), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column (70 g) on Analogix, eluted with MeOH in DCM (0 to 7.5%) to obtain 4.08g (80.3%) of the title compound as a gummy material. LCMS: Rx = 1.14 minutes, MS: 255 (M+H).
1H NMR (300 MHz, CDCl3): 3.30 (m, IH), 3.14 (bs, 2H), 2.91 (m, IH), 2.75 (m, IH), 2.51 (m, IH), 2.07-1.69 (m, 6H), 1.46 (s, 9H), 1.10 (d, 6.0Hz, 3H). Intermediate (xiv)
2-(2R)-Methyl-[l,3'(3'R)]bipyrrolidinyl-l'-carboxylic acid tert-butyl ester
Figure imgf000036_0001
The title compound was prepared in a manner substantially the same as intermediate (xiii) by condensing 3-(3S)-(toluene-4-sulfonyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester (Intermediate (xiii) obtained above) and R-(-)-2-methylpiperindine (obtained from Advanced Asymmetries). LCMS: Rx = 1.09 minutes, MS: 255 (M+H).
1H NMR (300 MHz, CDCl3): 3.15 (m, 2H), 3.3 (m, 3H), 2.97 (m, IH), 2.71 (m, IH), 2.47 (m, IH), 1.98 (m, 2H), 1.96-1.67 (m, 4H), 1.46 (s, 9H), 1.06 (d, 6.2Hz, 3H).
Intermediate (xv) Preparation of 2(2S)-methyl-[l,3'(3'R)]bipyrrolidinyl
Figure imgf000036_0002
2-(2S)-Methyl-[l,3'(3'R)]bipyrrolidinyl-r-carboxylic acid tert-butyl ester (7.91 g ,
31.14 mmol) was treated with 28.8 mL of HCl in dioxane at O0C. The solution was stirred under nitrogen at r.t. overnight. Both TLC (10% MeOH in DCM) and LC/MS did not detect the starting material. The reaction was judged complete. N2 was passed through the solution with stirring. The outlet was passed through KOH solution to absorb HCl for Ih. The solvent was removed by evaporation to dryness to get the title compound as a hygroscopic very thick gummy (2HCl salt, hydrated. Exact composition unknown), 8.07 g (-100 %). MS: 155 (M+H).
1H NMR: (D2O, 300 MHz): 11.6 (bs, IH), 9.1 (bs, IH) 4.12 ( m, IH) 3.5, (m, 2H), 3.3-3.1 ( m, 3H), 2.4-2.1 (m, 4H), 2.4(m, 2H), 1.6 (m, IH), 1.4(d, 6.0 Hz,3H).
Intermediate (xvi) 2(2S)-Methyl-[ 1 ,3'(3 ' S)]bipyrrolidinyl
Figure imgf000036_0003
The title compound was prepared in a manner substantially the same as intermediate (xv) by acid hydrolysis of 2-(2S)-methyl-[l,3'(3'S)]bipyrrolidinyl-r-carboxylic acid tert- butyl ester (Intermediate (x) obtained above). LCMS: Rx = 0.37 minutes, MS: 155 (M+H).
1H NMR: (D2O, 300 MHz): 11.6 (bs, IH), 9.1 (bs, IH) 4.12 ( m, IH) 3.5, (m, 2H), 3.3-3.1 (m, 3H), 2.4-2.1 (m, 4H), 2.4(m, 2H), 1.6 (m, IH), 1.4(d, 6.0 Hz,3H)
Intermediate (xvii) Preparation of 2(2R)-methyl- [ 1 ,3 ' (3 ' S)]bipyrrolidinyl
Figure imgf000037_0001
The title compound was prepared in a manner substantially the same as intermediate
(xv) by acid hydrolysis of 2-(2R)-methyl-[l,3'(3'S)]bipyrrolidinyl-r-carboxylic acid tert- butyl ester (Intermediate (xi) obtained above).
Intermediate (xviii)
2(2R)-Methyl-[1 ,3'(3 'R)]bipyrrolidinyl
Figure imgf000037_0002
The title compound was prepared in a manner substantially the same as intermediate (xv) by acid hydrolysis of 2-(2R)-methyl-[l,3'(3'R)]bipyrrolidinyl-r-carboxylic acid tert- butyl ester (Intermediate (xiv) obtained above). MS: 155 (M+H). 1H NMR: (D2O, 300 MHz): 11.6 (bs, IH), 9.1 (bs, IH) 4.12 ( m, IH) 3.5, (m, 2H), 3.3-3.1 (m, 3H), 2.4-2.1 (m, 4H), 2.4(m, 2H), 1.6 (m, IH), 1.4(d, 6.0 Hz,3H)
Intermediate (xix) 2-(2S)-Methyl- 1 '-(3-methyl-4-nitro-phenyl)-[ 1 ,3'(3 'R)]bipyrrolidinyl
Figure imgf000037_0003
2(2S)-Methyl-[l,3'(3'R)]bipyrrolidinyl (0.23 g, 1.2 mmol) was dissolved in anhydrous
DMSO (5 mL) in a flask. To this solution was added 5-fluoro-2-nitrotoluene (223 mg, 1.44 mmol), followed by powdered anhydrous potassium carbonate (662 mg, 4.8 mmol). The suspension was heated on an oil bath to 850C for 4h when the starting material was consumed as shown by TLC (5% MeOH/DCM) and LC/MS. MS: 290 (base peak).
To the suspension were added 2 mL of water and 5 mL of DCM. The two layers were separated, and the aqueous layer was extracted with DCM (10 mLx2). The combined DCM extracts were washed with sodium bicarbonate (5 mL), and brine (5 mLx2), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column, eluted with 5% MeOH in DCM to get the title compound as a yellow solid after drying. LCMS: Rx = 1.38 minutes, MS: 290 (M+H). 1H NMR (300 MHz, CDC13): 8.10 (d, 9.1Hz, IH), 6.36 (dd, 9.2, 2.5 Hz, IH), 6.28 (d, 2.4 Hz, IH), 3.654(m, 2H), 3.37 (m, 3H), 2.99 (dt, 3.7Hz, 8.8Hz, IH), 2.84 (sixtet, 6.6Hz, IH), 2.65 (s, 3H), 2.56 (q , 8.1Hz, IH), 2.31 (m, 2H), 2.11 (m ,2H) 1.87 (m,lH), 1.08 (d, 6.2Hz, 3H). Analytical chiral HPLC conditions: Isocratic 100% isopropanol with 0.5% IP Amine 5ml/min outlet pressure 150 bar, 200 nM; Results: Rx = 10.92 min; ee 100%
Intermediate (xx) 2-(2S)-Methyl- 1 '-(3-methyl-4-nitro-phenyl)-[ 1 ,3'(3 'S)]bipyrrolidinyl
Figure imgf000038_0001
The title compound was prepared in a manner substantially the same as intermediate (xix) by condensing 2(2S)-methyl-[l,3'(3S)]bipyrrolidinyl and 5-fluoro-2-nitrotoluene. LCMS: Rx = 1.43 minutes, MS: 290 (M+H).
1H NMR (300 MHz, CDCl3): 8.10 (d, 9.2Hz, IH), 6.36 (dd, 9.2, 2.8 Hz, IH), 6.28 (d, 2.2 Hz, IH), 3.6 (m, 2H), 3.3 (m, 3H), 3.00-2.78 (dt, 3.5Hz, 8.8Hz,2H), , 2.79 (m, IH), 2.64 (s, 3H), 2.56 (m, IH), 2.03 (m, 2H), 1.98 (m ,2H) 1.45 (m,lH), 1.08 (d, 6.2Hz, 3H). Analytical chiral HPLC conditions: Isocratic 100% isopropanol with 0.5% IP Amine 5ml/min outlet pressure 150 bar, 200 nM; Results: Rx = 8.16 min; ee 100%
Intermediate (xxi) 2-(2R)-Methyl-r-(3-methyl-4-nitro-phenyl)-[l,3'(3'S)]bipyrrolidinyl
Figure imgf000039_0001
The title compound was prepared in a manner substantially the same as intermediate (xix) by condensing 2(2R)-methyl-[l,3'(3'S)]bipyrrolidinyl and 5-fluoro-2-nitrotoluene. LCMS: Rx = 1.41 minutes, MS: 290 (M+H).
1H NMR (300 MHz, CDC13): 8.10 (d, 9.1Hz, IH), 6.36 (dd, 9.2, 2.5 Hz, IH), 6.28 (d, 2.4 Hz, IH), 3.654(m, 2H), 3.37 (m, 3H), 2.99 (dt, 3.7Hz, 8.8Hz, IH), 2.84 (sixtet, 6.6Hz, IH), 2.65 (s, 3H), 2.56 (q , 8.1Hz, IH), 2.31 (m, 2H), 2.11 (m ,2H) 1.87 (m,lH), 1.08 (d, 6.2Hz, 3H). Analytical chiral HPLC conditions: Isocratic 100% isopropanol with 0.5% IP Amine 5ml/min outlet pressure 150 bar, 200 nM; Results: Rx = 11.93 min; ee 100%
Intermediate (xxii) 2-(2R)-Methyl-r-(3-methyl-4-nitro-phenyl)-[l,3'(3'R)]bipyrrolidinyl
Figure imgf000039_0002
The title compound was prepared in a manner substantially the same as intermediate (xix) by condensing 2(2R)-Methyl-[l,3'(3'R)]bipyrrolidinyl and 5-fluoro-2-nitrotoluene. LCMS: Rx = 1.43 minutes, MS: 290 (M+H).
1H NMR (300 MHz, CDCl3): 8.10 (d, 9.2Hz, IH), 6.36 (dd, 9.2, 2.8 Hz, IH), 6.28 (d, 2.2 Hz, IH), 3.6 (m, 2H), 3.3 (m, 3H), 3.00-2.78 (dt, 3.5Hz, 8.8Hz,2H), , 2.79 (m, IH), 2.64 (s, 3H), 2.56 (m, IH), 2.03 (m, 2H), 1.98 (m ,2H) 1.45 (m,lH), 1.08 (d, 6.2Hz, 3H). Analytical chiral HPLC conditions: Isocratic 100% isopropanol with 0.5% IP Amine 5ml/min outlet pressure 150 bar, 200 nM; Results: Rx = 8.95 min; ee 100%
Intermediate (xxiii) 2-Methyl-4-(2-(2S)-methyl-[ 1 ,3'(3 'R)]bipyrrolidinyl- 1 '-yl)-phenylamine
Figure imgf000040_0001
A solution of 2-(2S)-methyl- 1 '-(3-methyl-4-nitro-phenyl)-[ 1 ,3'(3 'R)]bipyrrolidinyl (2.02 g, 6.98 mmol) in MeOH (40 mL) was de-aerated and nitrogen was introduced. To this solution was added Pd-C (10%, 0.2g). This mixture was stirred under H2 atmosphere at r.t. for 4h. TLC (10% MeOH in DCM) and LC/MS showed the reaction was complete, and the product was detected by MS at 261. The mixture was passed through a Celite pad, rinsed with methanol. The filtrate was concentrated to dryness, and further dried to yield the title compound as a reddish brown liquid after drying under high vacuum, 1.8 Ig (100%). LC/MS: 260, TLC (10%MeOH/DCM): 0.3 Rf. This material is used immediately without storage and/or further purification.
Intermediate (xxiv) 2-Methyl-4-(2-(2S)-methyl-[l ,3'(3 ' S)]bipyrrolidinyl- 1 '-yl)-phenylamine
Figure imgf000040_0002
The title compound was prepared in a manner substantially the same as intermediate (xxiii) by hydrogenation of 2-(2S)M ethyl- l'-(3-methyl-4-nitro-phenyl)-
[l,3'(3'S)]bipyrrolidinyl. LC/MS: 260, TLC (10%MeOH/DCM): 0.3 Rf.
Intermediate (xxv) 2-Methyl-4-(2-(2R)-methyl-[ 1 ,3'(3 ' S)]bipyrrolidinyl- 1 '-yl)-phenylamine
Figure imgf000040_0003
The title compound was prepared in a manner substantially the same as intermediate (xxiii) by hydrogenation of 2-(2R)-methyl-l'-(3-methyl-4-nitro-phenyl)-
[l,3'(3'S)]bipyrrolidinyl. LC/MS: 260, TLC (10%MeOH/DCM): 0.3 Rf.
Intermediate (xxvi) 2-Methyl-4-(2(2R)-methyl-[l,3'(3'R)]bipyrrolidinyl-r-yl)-phenylamine
Figure imgf000041_0001
The title compound was prepared in a manner substantially the same as intermediate (xxiii) by hydrogenation of 2-(2R)-M ethyl- 1'-(3 -methyl-4-nitro-phenyl)- [l,3'(3'R)]bipyrrolidinyl. LC/MS: 260, TLC (10%MeOH/DCM): 0.3 Rf.
Example 1 4-Fluoro-N-[2-methyl-4-(2(2S)-methyl-[ 1 ,3'(3 ' S)]bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide
Figure imgf000041_0002
2-Methyl-4-(2(2S)-methyl-[l,3'(3'S)]bipyrrolidinyl-r-yl)-phenylamine (200mg, 0.77 mmol) was dissolved in DCM (10 mL). To this solution was transferred a solution of A- fluoro-benzoyl chloride (from Alfa Aesar, 222 mg, 1.4 mmol) in DCM (2 mL), followed by pyridine (1 mL) at O0C. The solution was stirred at O0C for 30 min. The ice-water bath was removed and the reaction was stirred at r.t. for 1.5h when TLC (10% MeOH in DCM) and LC/MS showed that the reaction was complete and the product peak (396) was detected. The reaction was quenched with polymer bounded diethylenetriamine (4 mmol/g, 0.25g), stirring at r.t. for 30 min, then filtered and rinsed with DCM. The solvent was evaporated to dryness, re-dissolved in DCM and washed with aqueous sodium bicarbonate solution. The two layers were separated, and the aqueous layer was extracted with DCM (5 mLx2). The combined DCM extracts were again washed with sodium bicarbonate solution (5 mL), and brine (5 mLx2), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column, eluted successively with 2%, 7.5%, and 10% MeOH in DCM to obtain the title compound as a yellow tan solid in the form of a free base. This material was dissolved in DCM and ether (1 :1 v/v, 5 mL), treated with IN HCl (1 mL) at 00C. The solvent was evaporated and dried under high vacuum to obtain the title compound as a tan solid. LCMS: Rx = 2.26 minutes, MS: 382 (M+H).
1H NMR (CDCl3, 300MHz), δ (ppm): 8.06 (m, IH), 7.89 (m, IH), 7.47 (m, IH), 7.15 (m, IH), 7.06 (m, IH), 6.43-6.46 (m, 2H), 3.56 (m, 2H), 3.42 (m, 2H), 3.30 (m, 2H), 3.07 (m, IH), 2.78 (m, IH), 2.27 (s, 3H), 2.21 (m, 2H), 2.05 - 1.80(m, 3H), 1.65 (m, IH), 1.29 (d, 6.3Hz, 3H).
Example 2
5 -Fluoro-2-methyl-N- [3 -methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- l'-yl)-phenyl] -benzamide trifluoro-acetate
Figure imgf000042_0001
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(3-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 5-fluoro-2- methylbenzoyl chloride (from Alfa Aesar). MS: 396.3 (M+H). Example 3
5-Fluoro-2-methyl-N-[2-methyl-4-(2(2S)-methyl-[l,3'(3'R)]bipyrrolidinyl-r-yl)- phenyl] -benzamide
Figure imgf000042_0002
2-Methyl-4-(2(2S)-methyl-[l,3'(3'R)]bipyrrolidinyl-r-yl)-phenylamine (200mg, 0.77 mmol) was dissolved in DCM (10 mL). To this solution was added a solution of 5-fluoro-2- methylbenzoyl chloride (from Alfa Aesar, 242 mg, 1.4 mmol) in DCM (2 mL), followed by pyridine (1 mL) at O0C. The solution was stirred at O0C for 30 min. The ice-water bath was removed and the reaction was stirred at r.t. for 1.5h when TLC (10% MeOH in DCM) and LC/MS showed that the reaction was complete and the product peak (396) was detected. The reaction was quenched with polymer bound diethylenetriamine (4 mmol/g, 0.25 g), stirring at r.t. for 30 min, then filtered and rinsed with DCM. The solvent was evaporated to dryness, re- dissolved in DCM and aqueous sodium bicarbonate solution. The two layers were separated, and the aqueous layer was extracted with DCM (5 mLx2). The combined DCM extracts were washed with sodium bicarbonate (5 mL), and brine (5 mLx2), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column, eluted successively with 2%, 7.5%, and 10% MeOH in DCM to obtain the title compound in the form of a free base as a yellow tan solid. This material was dissolved in DCM and ether (1 :1 v/v, 5 mL), treated with IN HCl (1 mL) at 00C. The solvent was evaporated and dried under high vacuum to obtain the title compound as a tan solid. LCMS: Rx = 1.61 minutes, MS: 396 (M+H).
1H NMR (DMSO-d6, 300MHz), δ (ppm): 10.8 (bs, IH), 9.59 (bs, IH), 7.32 (m, 2H), 7.14 (m, IH), 7.17(m, 2H), 6.51(m, 2H), 4.15 (m, IH), 3.56 (m, 4H), 3.48 (m, IH), 3.39 (m, IH), 3.23 (m, 2H), 2.5-2.4(m, 3H), 2.38 (s, 3H), 2.22 (s, 3H), 1.95 (m, 2H), 1.66 (m, IH), 1.45 (d, 6.4Hz, 3H).
Example 4
N-[4-(2-Methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-3-trifluoromethyl-benzamide trifluoro- acetate
Figure imgf000043_0001
The title compound was prepared in a manner substantially the same as Example 1 by coupling 4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 3 -trifluoromethyl-benzoyl chloride. MS: 418.2 (M+H).
Example 5
5-Fluoro-2-methyl-N-[2-methyl-4-(2(2R)-methyl-[l,3'(3'S)]bipyrrolidinyl-r-yl)- phenyl] -benzamide
Figure imgf000043_0002
2-Methyl-4-(2(2R)-methyl-[ 1 ,3'(3 ' S)]bipyrrolidinyl- 1 '-yl)-phenylamine (200mg, 0.77 mmol) was dissolved in DCM (10 mL). To this solution was added a solution of 5-fluoro-2- methylbenzoyl chloride (from Alfa Aesar, 242 mg, 1.4 mmol) in DCM (2 mL), followed by pyridine (1 rnL) at 00C. The solution was stirred at 00C for 30 min. The ice-water bath was removed and the reaction was stirred at r.t. for 1.5h when TLC (10% MeOH in DCM) and LC/MS showed that the reaction was complete and the product peak (396) was detected. The reaction was quenched with polymer bound diethylenetriamine (4 mmol/g, 0.25 g), stirring at r.t. for 30 min, then filtered and rinsed with DCM. The solvent was evaporated to dryness, re- dissolved in DCM and NaHCO3 aqueous solution. The two layers were separated, and the aqueous layer was extracted with DCM (5 mLx2). The combined DCM extracts were washed with sodium bicarbonate (5 mL), and brine (5 mLx2), dried (anhydrous potassium carbonate), filtered, and concentrated in vacuo. The crude product was purified on a silica gel column by eluting successively with 2%, 7.5%, and 10% MeOH in DCM to obtain the title compound as a yellow tan solid in the form of a free base. This material was dissolved in DCM and ether (1 : 1 v/v, 5 mL), treated with IN HCl (1 mL) at 00C. The solvent was evaporated and dried under high vacuum to obtain the title compound as a tan solid. LCMS: RT = 1.59 minutes, MS: 396 (M+H). 1H NMR (DMSO-d6, 300MHz), δ (ppm): 10.8 (bs, IH), 9.59 (bs, IH), 7.32 (m, 2H), 7.14 (m, IH), 7.17(m, 2H), 6.51(m, 2H), 4.15 (m, IH), 3.56 (m, 4H), 3.48 (m, IH), 3.39 (m, IH), 3.23 (m, 2H), 2.5-2.4(m, 3H), 2.38 (s, 3H), 2.22 (s, 3H), 1.95 (m, 2H), 1.66 (m, IH), 1.45 (d, 6.4Hz, 3H).
Example 6 2-Fluoro-N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide
Figure imgf000044_0001
2-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine (1.52 g, 5.84 mmol) was dissolved in DCM (30 mL). To this solution was transferred a solution of 2-fluorobenzoyl chloride in DCM (2 mL), followed by pyridine (7.5 mL). The solution was stirred at r.t. for 2h when TLC (10% MeOH in DCM) and LC/MS showed that the reaction was complete. The reaction was quenched with polymer bounded diethylenetriamine (4 mmol/g, 1.5g) and the suspension was stirred for 30 min. Then, 10 mL of DCM was added to the suspension and the suspension was filtered through a Celite pad, rinsed with DCM and 10%MeOH in DCM. The crude product was purified on a silica gel column eluted with 2%, 5% and 7.5% MeOH in DCM to obtain the title compound as a yellow solid, 1.79 g (80%). LCMS: Rx = 1.53 minutes, MS: 382 (M+H).
1H NMR (CDCI3, 300MHz), δ (ppm): Two sets of signals were observed in about 1 :1.2 ratio and the spectra were closely overlapping. The observed chemical shifts are as follows: 8.26 (m), 7.78 (m), 7.65 (m), 7.5 (m), 7.3 (m), 7.15 (m), 6.4 (m), 3.5-3.2 (m), 3.00 (m), 2.80 (m), 2.55 (m), 2.3 (m), 2.10-1.6 (m), 2.45 (m), 1.08 (d).
Example 7 4-Fluoro-N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide
Figure imgf000045_0001
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-y l)-phenylamine with 4-fluorobenzoyl chloride. LCMS: Rx = 1.54 minutes, MS: 382 (M+H).
1H NMR (CDCI3, 300MHz), δ (ppm): Two sets of signals were observed and the spectra were closely overlapping. The observed chemical shifts are as follows: 1.86 (m), 7.48, 7.13 (m), 7.11 (m), 6.41(m), 3.53-3.34 (m), 2.29 (m), 2.89 (m), 2.62 (m), 2.60-1.77 (m), 1.57 (m), 1.21 (d, 6.1Hz), 1.20 (d, 5.8Hz).
Example 8 2-Fluoro-N-[2-methyl-4-(2-(2R)-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide
Figure imgf000045_0002
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-(R)-methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 2- fluorobenzoyl chloride. LCMS: Rx = 1.70 minutes, MS: 382 (M+H).
1H NMR (CDCl3, 300MHz), δ (ppm): Two sets of signals were observed in about 1 :1.2 ratio and the spectra were closely overlapping. The observed chemical shifts are as follows: 12.5 (bs), 8.26 (m), 8.00 (m), 7.78 (m), 7.60 (m), 7.3 (m), 6.55(m), 4.2 (bs), 3.98 (bs), 3.68-3.34 (m), 2.29 (m), 2.89 (m), 2.62 (m), 1.90 (m), 1.6 (m).
Example 9 4-Fluoro-N-[2-methyl-4-(2-(2R)-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide
Figure imgf000046_0001
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-(R)-methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 4- fluorobenzoyl chloride. LCMS: Rx = 1.57 minutes, MS: 382 (M+H).
1H NMR (CDCI3, 300MHz), δ (ppm): Two sets of signals were observed in about 1 :3 ratio and the spectra were closely overlapping. The observed chemical shifts are as follows: 12.8 (bs), 7.86(m), 7.48, 7.13-6.95 (m), 6.45(m), 4.2 , 3.9 , 3.85-3.10 (m), 2.6-2.0 (m), 2.62 (m), 2.0-1.57 (m).
Example 10 5 -Fluoro-2-methyl-N- [2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- l'-yl)-phenyl] -benzamide
Figure imgf000046_0002
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 5-fluoro-2- methyl-benzoyl chloride (from Alfa Aesar). LCMS: Rx = 1.56 minutes, MS: 396 (M+H). 1H NMR (CDCl3, 300MHz), δ (ppm): 7.48 (d, 7.4Hz, IH), 7.23 (m, 2H), 7.04 (m, IH), 6.42 (m, 2H), 3.53 - 3.05 (m, 6H), 2.81 (m, IH), 2.54 (m, IH), 2.49 (bs, 3H), 2.28 (bs, 3H), 2.2- 1.95 (m, 3H), 1.70 (m, 4H), 1.15 (d, 6.0Hz, 3H).
Example 11
5-Fluoro-2-methyl-N-[2-methyl-4-(2-(2S)-methyl-[ 1 ,3' (3'S)]bipyrrolidinyl- 1 '-yl)-phenyl]- benzamide
Figure imgf000046_0003
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-(S)-methyl-[l,3' (S)]bipyrrolidinyl-r-yl)-phenylamine with 5-fluoro- 2-methyl-benzoyl chloride (from Alfa Aesar). LCMS: Rx = 2.14 minutes, MS: 396 (M+H). 1H NMR (CDCl3, 300MHz), δ (ppm): 7.48 (d, 7.4Hz, IH), 7.23 (m, IH), 7.04 (m, 2H), 6.42 (m, 2H), 3.53 (m, IH), 3.40-3.27 (m, 4H), 3.05 (m, IH), 2.81 (m, IH), 2.54 (m, IH), 2.49 (bs, 3H), 2.28 (bs, 3H), 2.2-1.95 (m, 3H), 1.70 (m, 4H), 1.15 (d, 6.0Hz, 3H).
Example 12
5-Fluoro-2-methyl-N-[2-methyl-4-(2-(R)-methyl-[l,3' (R)]bipyrrolidinyl-r-yl)-phenyl]- benzamide hydrochloride
Figure imgf000047_0001
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-(R)-methyl-[l,3' (R)]bipyrrolidinyl-r-yl)-phenylamine with 5-fluoro- 2-methyl-benzoyl chloride (from Alfa Aesar). LCMS: Rx = 1.61 minutes, MS: 396 (M+H).
1H NMR (CDCl3, 300MHz), δ (ppm): 7.48 (d, 7.4Hz, IH), 7.23 (m, IH), 7.04 (m, 2H), 6.42 (m, 2H), 3.53 (m, IH), 3.40-3.27 (m, 4H), 3.05 (m, IH), 2.81 (m, IH), 2.54 (m, IH), 2.49 (bs, 3H), 2.28 (bs, 3H), 2.2-1.95 (m, 3H), 1.70 (m, 4H), 1.15 (d, 6.0Hz, 3H).
Example 13 3-Fluoro-N-[2-methyl-4-(2-(S)-methyl-[l,3' (S)]bipyrrolidinyl-r-yl)-phenyl]-benzamide
Figure imgf000047_0002
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-(S)-methyl-[l,3' (S)]bipyrrolidinyl-r-yl)-phenylamine with 3-fluoro- benzoic acid. LCMS: Rx = 2.26 minutes, MS: 382 (M+H). 1H NMR (CDCl3, 300MHz), δ (ppm): 7.65 (m, 2H), 7.47 (m, 2H), 7.23 (m, IH), 6.45-6.42 (m, 2H), 3.54 (t, 7.5Hz, IH), 3.39 (m, 3H), 3.31 (m, IH), 3.10 (m, IH), 2.88 (m, IH), 2.60 (q, 8.4Hz, IH), 2.28 (s, 3H), 2.23-1.71 (m, 5H), 1.53 (m, IH), 1.19 (d, 6.3Hz, 3H).
Example 14 4-Chloro-N-[2-methyl-4-(2-(S)-methyl-[l,3' (S)]bipyrrolidinyl-r-yl)-phenyl]-benzamide
Figure imgf000048_0001
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-(S)-methyl-[l,3' (S)]bipyrrolidinyl-r-yl)-phenylamine with 4-chloro- benzoyl chloride. LCMS: Rx = 3.96 minutes, MS: 398 (M+H).
1H NMR (CDCl3, 300MHz), δ (ppm): 8.19 (m, IH), 7.94 (m, IH), 7.46 (d, 7.2Hz, IH), 7.23 (m, IH), 6.43-6.46 (m, 2H), 3.56 (m, 2H), 3.53 (m, IH), 3.40-3.24 (m, 3H), 3.1 (m, IH), 2.78- 2.50 (m, 3H), 2.27 (s, 3H), 2.21 (m, 2H), 2.05 - 1.80(m, 3H), 1.75 (m, IH), 1.50 (m, IH), 1.17 (d, 6.3Hz, 3H).
Example 15 5 -Fluoro-2-methyl-N- [2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- l'-yl)-phenyl] -benzamide
Figure imgf000048_0002
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-(S)-methyl-[l,3' (S)]bipyrrolidinyl-r-yl)-phenylamine with 5-fluoro- 2-trifluoromethyl-benzoyl chloride. LCMS: Rx = 2.53 minutes, MS: 450 (M+H). 1H NMR (CDCl3, 300MHz), δ (ppm): 7.78 (dd, 5.1Hz, 8.4Hz, IH), 7.49 (d, 8.4Hz, IH), 7.74 (dd, 2.7Hz, 8.4Hz, IH), 7.06 (s, IH), 6.46-6.42 (m, 2H), 3.55 (m, IH), 3.43 (m, 2H), 3.31 (m, 2H), 2.92 (m, IH), 2.64 (m, IH), 2.28 (s, 3H), 2.24-1.51 (m, 7H), 1.22 (d, 6.6Hz, 3H).
Example 16
2,3-Dihydro-benzofuran-5-carboxylic acid [2-methyl-4-(2(2S)-methyl- [l,3'(3'S)]bipyrrolidinyl-r-yl)-phenyl]-amide, trifluoro-acetic acid
Figure imgf000049_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(2S)-methyl-[l,3'(3'S)]bipyrrolidinyl-r-yl)-phenylamine with 2,3- dihydro-benzofuran-5-carbony chloride. LCMS: Rx = 1.19 minutes, MS: 406.2 (M+H).
Example 17 4-Methanesulfonyl-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000049_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4- methanesulfonyl-benzoyl chloride. MS: 442.2 (M+H).
Example 18 2-Fluoro-N- [4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl] -benzamide trifluoroacetate
Figure imgf000049_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 2-fluoro- benzoyl chloride. MS: 436.2 (M+H).
Example 19 4-Difluoromethoxy-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide
Figure imgf000050_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-difluoro- methoxy-benzoyl chloride. MS: 430.2 (M+H).
Example 20 3-Fluoro-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000050_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 3-fluoro-benzoyl chloride. MS: 368.2 (M+H).
Example 21
(E)-N-[4-(2-Methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-3-pyridin-3-yl-acrylamide trifluoroacetate
Figure imgf000050_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 3 -pyridin-3 -yl-acryloyl chloride. MS: 377.3 (M+H).
Example 22
2,5-Dioxo-2,3,4,5-tetrahydro-lH-benzo[e][l,4]diazepine-8-carboxylic acid [2-methyl-4-(2- methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenyl] -amide
Figure imgf000051_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 2,5-Dioxo- 2,3,4,5-tetrahydro-lH-benzo[e][l,4]diazepine-8-carboxylic acid. MS: 462.3 (M+H).
Example 23
4-Cyano-N- [2-methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000051_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-cyano-benzoyl chloride. MS: 389.2 (M+H).
Example 24 3-Fluoro-N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000051_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-fluoro-benzoyl chloride. MS: 382.2 (M+H).
Example 25
Tetrahydro-furan-2-carboxylic acid [2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)- phenyl] -amide trifluoroacetate
Figure imgf000052_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)-phenylamine with tetrahydro- furan-2-carboxylic acid. MS: 358.2 (M+H).
Example 26
6-Chloro-imidazo[l ,2-a]pyridine-2-carboxylic acid [2-methyl-4-(2-methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide
Figure imgf000052_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 6-Chloro- imidazo[l,2-a]pyridine-2-carboxylic acid. MS: 438.4 (M+H).
Example 27
N-[2-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-3-trifluoromethyl-benzamide trifluoroacetate
Figure imgf000052_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-trifluoro- methyl-benzoyl chloride. MS: 432.2 (M+H).
Example 28
Thiophene-2-carboxylic acid [2 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide trifluoroacetate
Figure imgf000053_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with thiophene-2- carboxylic acid. MS: 370.2 (M+H).
Example 29
4-0x0-4,5 ,6,7-tetrahydro-benzofuran-2-carboxylic acid [2-methyl-4-(2-methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide
Figure imgf000053_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-oxo-4,5,6,7- tetrahydro-benzofuran-2-carboxylic acid. MS: 422.4 (M+H).
Example 30
4-Isopropyl-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-3-sulfamoyl- benzamide
Figure imgf000053_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-isopropyl-3- sulfamoyl-benzoic acid. MS: 485.3 (M+H).
Example 31 N-[2-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-4-(lH-pyrazol-3-yl)-benzamide
Figure imgf000054_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-(lH-pyrazol-3- yl)-benzoic acid. MS: 430.3 (M+H).
Example 32 Benzofuran-5-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -amide
Figure imgf000054_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with benzofuran-5 - carboxylic acid. MS: 404.4 (M+H).
Example 33 β-Methoxy-benzofuran^-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl]-amide
Figure imgf000054_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 6-methoxy- benzofuran-2-carboxylic acid. MS: 434.2 (M+H).
Example 34
2-Pyridin-3-yl-lH-benzoimidazole-5 -carboxylic acid [2-methyl-4-(2-methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenyl]-amide
Figure imgf000055_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-pyridin-3-yl- lH-benzoimidazole-5-carboxylic acid. MS: 481.3 (M+H).
Example 35
6-Chloro-4-oxo-4H-chromene-2-carboxylic acid [2-methyl-4-(2-methyl-[l ,3']bipyrrolidinyl-
1 '-yl)-phenyl] -amide
Figure imgf000055_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 6-chloro-4-oxo- 4H-chromene-2-carboxylic acid. MS: 466.2 (M+H).
Example 36 N-[2-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-nicotinamide trifluoro-acetate
Figure imgf000055_0003
The title compound was prepared in a manner substantially the same as Example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with pyridine-3- carboxylic acid. MS: 365.22 (M+H).
Example 37 lH-Indole-2-carboxylic acid [4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide trifluoro- acetate
Figure imgf000056_0001
The title compound was prepared in a manner substantially the same as Example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with lH-Indole-2-carboxylic acid. MS: 389.22 (M+H).
Example 38
5-Chloro-6-(2-hydroxy-ethylamino)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- pheny 1] -nicotinamide
Figure imgf000056_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 5-chloro-6-(2- hydroxy-ethylamino)-nicotinic acid. MS: 458.4 (M+H).
Example 39 6-Benzyloxymethyl-N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -nicotinamide
Figure imgf000056_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 6-benzyloxy- methyl-nicotininic acid. MS: 485.5 (M+H).
Example 40
2-Pyridin-4-yl-thiazole-4-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl]-amide
Figure imgf000057_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-pyridin-4-yl- thiazole-4-carboxylic acid. MS: 448.2 (M+H).
Example 41 Thiophene-2-carboxylic acid [3 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide trifluoroacetate
Figure imgf000057_0002
The title compound is prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with thiophene-2- carboxylic acid. MS: 370.2 (M+H).
Example 42
4-(4,6-Dimethyl-pyrimidin-2-ylamino)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl] -benzamide
Figure imgf000057_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 4-(4,6-dimethyl- pyrimidin-2-ylamino) benzoic acid. MS: 485.3 (M+H).
Example 43 l-Acetyl-pyrrolidine-2-carboxylic acid [4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide trifluoroacetate
Figure imgf000058_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 1 -acetyl-pyrrolidine -2- carboxylic acid. MS: 385.3 (M+H).
Example 44
5-Fluoro-2-methyl-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000058_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 5 -fluoro-2 -methyl benzoic acid. MS: 382.3 (M+H).
Example 45 lH-Indole-2-carboxylic acid [3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide trifluoroacetate
Figure imgf000058_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with lH-Indole-2- carboxylic acid. MS: 403.3 (M+H).
Example 46 3 -Dimethylamino-N-[3 -methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenyl] -benzamide trifluoroacetate
Figure imgf000058_0004
.CF3CO2H The title compound was prepared in a manner substantially the same as example 1 by coupling 3 -methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 3 -dimethyl- amino benzoic acid. MS: 407.3 (M+H).
Example 47
N-[2-Methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-2-phenoxy-acetamide trifluoroacetate
Figure imgf000059_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 'Jbipyrrolidinyl- r-yl)-phenylamine with 2-phenoxy-acetic acid. MS: 394.2 (M+H).
Example 48
4-Methanesulfonyl-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000059_0002
.CF3CO2H The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1 , 3 'Jbipyrrolidinyl- l'-yl)-phenylamine with 4-methane- sulfonyl benzoic acid. MS: 442.2 (M+H).
Example 49
S-Methoxy-benzofuran^-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-l'-yl)- phenylj-amide
Figure imgf000059_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 5 -methoxy- benzofuran-2-carboxylic acid. MS: 434.2 (M+H). Example 50
4-Hydroxy-7-methyl-[l ,8]naphthyridine-3-carboxylic acid [2-methyl-4-(2-methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide
Figure imgf000060_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-hydroxy-7- methyl-[l,8]naphthyridine-3-carboxylic acid. MS: 446.5 (M+H).
Example 51
2-Pyridin-2-yl-lH-benzoimidazole-5-carboxylic acid [2-methyl-4-(2-methyl- [1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -amide
Figure imgf000060_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-pyridin-2-yl- lH-benzoimidazole-5-carboxylic acid. MS: 481.3 (M+H). Example 52 lH-Indole-5-carboxylic acid [2-methyl-4-(2(S)-methyl-[l,3'(S)]-bipyrrolidinyl-r-yl)-phenyl]- amide trifluoroacetate
Figure imgf000060_0003
^0 .CF3CO2H
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)-phenylamine with lH-indole- 5-carboxylic acid. MS: 403.4 (M+H).
Example 53
Benzo[ 1 ,3]dioxole-5-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ?-yl)- phenyl]-amide
Figure imgf000061_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with benzo[l,3]- dioxole-5-carboxylic acid. MS: 408.4 (M+H).
Example 54
4-(Formyl-methyl-amino)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]- benzamide
Figure imgf000061_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-(formyl- methyl-amino)-benzoic acid. MS: 421.3 (M+H).
Example 55
4-(l-Acetyl-piperidin-3-yl)-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]- benzamide
Figure imgf000061_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 4-(l-acetyl- piperidin-3-yl)-benzoic acid. MS: 489.3 (M+H).
Example 56 2-Fluoro-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000061_0004
.CF3CO2H The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-fluoro-benzoic acid. MS: 368.2 (M+H).
Example 57
N-[2-Methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-4-(6-oxo-l ,6-dihydro-pyridin-3- yl)-benzamide
Figure imgf000062_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-(6-oxo-l,6- dihydro-pyridin-3-yl)-benzoic acid. MS: 457.3 (M+H).
Example 58
N-[2-Methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-4-morpholin-4-ylmethyl- benzamide trifluoroacetate
Figure imgf000062_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 4-morpholin-4- ylmethyl-benzoic acid. MS: 463.4 (M+H).
Example 59
(E)-3-(3-Fluoro-phenyl)-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-acrylamide trifluoroacetate
Figure imgf000062_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with (E)-3-(3-fluoro-phenyl)- acrylic acid. MS: 394.2 (M+H). Example 60
(E)-N- [4-(2-Methyl- [ 1 ,3 ']bipyrrolidinyl- r-yl)-2-trifluoromethyl-phenyl] -3 -pyridin-3 -yl- acrylamide trifluoroacetate
Figure imgf000063_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with (E)-3- pyridin-3-yl-acrylic acid. MS: 445.2 (M+H).
Example 61 l-Acetyl-pyrrolidine-2-carboxylic acid [3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl] -amide trifluoroacetate
Figure imgf000063_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 1-acetyl- pyrrolidine-2-carboxylic acid. MS: 399.2 (M+H). Example 62
Pyridine-2,5-dicarboxylic acid 2-[(2-methoxy-ethyl)-amide] 5-{[2-methyl-4-(2-methyl-
[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide}
Figure imgf000063_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with pyridine-2,5- dicarboxylic acid 2-[(2-methoxy-ethyl)-amide]. MS: 466.3 (M+H).
Example 63 2,4-Dimethyl-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]-benzamide
Figure imgf000064_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 2,4- dimethyl benzoyl chloride. MS: 446.2 (M+H).
Example 64
4-(3 ,5 -Dimethyl- 1 H-pyrazol-4-yl)-N-[2-methyl-4-(2-methyl- [ 1 ,3 ']bipyrrolidinyl- 1 '-yl)- phenyl] -benzamide
Figure imgf000064_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 4-(3,5-dimethyl- lH-pyrazol-4-yl) benzoic acid. MS: 458.3 (M+H).
Example 65
N-[2-Methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-4-(2-oxo-pyrrolidin- 1 -yl)- benzamide
Figure imgf000064_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-(2-oxo- pyrrolidin-l-yl)-benzoic acid. MS: 447.5 (M+H).
Example 66 lH-Indole-6-carboxylic acid [2-methyl-4-(2(S)-methyl-[l,3'(S)]-bipyrrolidinyl-r-yl)-phenyl]- amide trifluoroacetate
Figure imgf000065_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)-phenylamine with lH-indole- 6-carboxylic acid. MS: 403.4 (M+H).
Example 67
Imidazo[l,2-a]pyridine-8-carboxylic acid [4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]- amide trifluoroacetate
Figure imgf000065_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with imidazo-[l,2-a]pyridine-8- carboxylic acid. MS: 390.3 (M+H).
Example 68 4-Cyano-N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000065_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-cyano-benzoic acid. MS: 389.2 (M+H).
Example 69
Imidazo[l ,2-a]pyridine-8-carboxylic acid [3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ?-yl)- phenyl] -amide trifluoroacetate
Figure imgf000066_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with imidazo-[l,2- a]pyridine-8-carboxylic acid. MS: 404.3 (M+H).
Example 70 lH-Indole-2-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide trifluoroacetate
Figure imgf000066_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with lH-indole-2- carboxylic acid. MS: 403.2 (M+H).
Example 71
2-Methanesulfonyl-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-acetamide trifluoroacetate
Figure imgf000066_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 2-methane- sulfonyl-acetic acid. MS: 380.2 (M+H).
Example 72
6-Fluoro-2-methyl-quinoline-3-carboxylic acid [2 -methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '- yl)-phenyl]-amide
Figure imgf000067_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 6-fluoro-2- methyl-quinoline-3-carboxylic acid. MS: 447.4 (M+H).
Example 73
Benzofuran-6-carboxylic acid [2-methyl-4-(2(S)-methyl-[ 1 ,3'(S)]bipyrrolidinyl- 1 '-yl)-phenyl]- amide trifluoroacetate
Figure imgf000067_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[ 1 ,3'(S)]bipyrrolidinyl- 1 '-yl)-phenylamine with benzofuran-6-carboxylic acid. MS: 404.2 (M+H).
Example 74
(E)-3-(3-Fluoro-phenyl)-N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]- acrylamide trifluoroacetate
Figure imgf000067_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with (E)-3-(3-fluoro- phenyl)-acrylic acid. MS: 408.2 (M+H).
Example 75
2-Methanesulfonyl-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-acetamide trifluoroacetate
Figure imgf000068_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-methane- sulfonyl-acetic acid. MS: 380.2 (M+H).
Example 76 l-Acetyl-pyrrolidine-2-carboxylic acid [2-methyl-4-(2-methyl-[l ,3']bipyrrolidinyl-l'-yl)- phenyl] -amide trifluoroacetate
Figure imgf000068_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 1-acetyl- pyrrolidine-2-carboxylic acid. MS: 399.3 (M+H).
Example 77
4-Chloro-N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000068_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-chloro-benzoyl chloride. MS: 398.2 (M+H).
Example 78 lH-Indole-5-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide
Figure imgf000069_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with lH-indole-5- carboxylic acid. MS: 403.3 (M+H).
Example 79 N-[2-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-4-oxazol-5-yl-benzamide
Figure imgf000069_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 4-oxazol-5-yl- benzoyl chloride. MS: 431.3 (M+H).
Example 80
3-Methoxy-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]-benzamide trifluoroacetate
Figure imgf000069_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenylamine with 3 - methoxy-benzoyl chloride. MS: 448.2 (M+H).
Example 81
4-Chloro-N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000069_0004
.CF3CO2H The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-chloro-benzoyl chloride. MS: 398.2 (M+H).
Example 82 4-Dimethylamino-N- [4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000070_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-dimethylamino-benzoic acid. MS: 393.2 (M+H).
Example 83
2,3-Dihydro-benzo[l,4]dioxine-6-carboxylic acid [2 -methyl-4-(2 -methyl- [1,3 'Jbipyrrolidinyl-
1 '-yl)-phenyl] -amide
Figure imgf000070_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2,3-dihydro- benzo[l,4]dioxine-6-carboxylic acid. MS: 422.4 (M+H).
Example 84
5-Fluoro-2-methyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]- benzamide trifluoroacetate
Figure imgf000070_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 5-fluoro- 2-methyl benzoyl chloride. MS: 450.2 (M+H). Example 85 3 -Dimethylamino-N- [4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenyl] -benzamide trifluoroacetate
Figure imgf000071_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-dimethylamino benzoic acid. MS: 393.3 (M+H).
Example 86
6-Methyl-pyridine-2-carboxylic acid [2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)- phenyl] -amide trifluoroacetate
Figure imgf000071_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2(S)-methyl-[l,3'(S)]bipyrrolidinyl-r-yl)-phenylamine with 6-methyl- pyridine-2-carboxylic acid. MS: 379.2 (M+H).
Example 87 4-Methoxy-N- [3 -methyl-4-(2 -methyl- [1, 3 'Jbipyrrolidinyl- l'-yl)-phenyl] -benzamide trifluoroacetate
Figure imgf000071_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3 -methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 4-methoxy- benzoyl chloride. MS: 394.2 (M+H).
Example 88
2-Pyridin-3-yl-thiazole-4-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-l'-yl)- phenyl]-amide
Figure imgf000072_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-pyridin-3-yl- thiazole-4-carboxylic acid. MS: 448.2 (M+H).
Example 89
3,5-Dichloro-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]-benzamide trifluoroacetate
Figure imgf000072_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 3,5- dichloro-benzoyl chloride. MS: 486.1 (M+H).
Example 90
2-Methyl-lH-benzoimidazole-5-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r- yl)-phenyl]-amide
Figure imgf000072_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 2-methyl-lH- benzoimidazole-5-carboxylic acid. MS: 418.3 (M+H).
Example 91 3,5-Dichloro-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000072_0004
.CF3CO2H The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3,5-dichloro-benzoyl chloride. MS: 418.1 (M+H).
Example 92
N-[3 -Methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenyl] -3 -trifluoromethyl-benzamide trifluoroacetate
Figure imgf000073_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-trifluoro- methyl-benzoyl chloride. MS: 432.2 (M+H).
Example 93
2-Fluoro-N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000073_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-fluoro-benzoyl chloride. MS: 382.2 (M+H).
Example 94
3-Phenyl-propynoic acid [3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -amide trifluoroacetate
Figure imgf000073_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-phenyl- propynoic acid. MS: 388.2 (M+H). Example 95
6-Methyl-4-oxo-4H-chromene-2-carboxylic acid [2-methyl-4-(2-methyl-[l ,3']bipyrrolidinyl-
1 '-yl)-phenyl] -amide
Figure imgf000074_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 6-methyl-4-oxo- 4H-chromene-2-carboxylic acid. MS: 446.4 (M+H).
Example 96
[ 1 ,6]Naphthyridine-2-carboxylic acid [2-methyl-4-(2-methyl-[l ,3']bipyrrolidinyl- 1 ?-yl)- phenyl]-amide
Figure imgf000074_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with
[l,6]naphthyridine-2-carboxylic acid. MS: 416.4 (M+H). Example 97
3-Methanesulfonyl-4-methyl-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]- benzamide
Figure imgf000074_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 'Jbipyrrolidinyl- l'-yl)-phenylamine with 3-methane- sulfonyl-4-methyl-benzoyl chloride. MS: 456.2 (M+H).
Example 98
4- {4-[2-Methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenylcarbamoyl]-phenoxy} -benzoic acid
Figure imgf000075_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4,4'- biscarboxydiphenyl ether. MS: 500.3 (M+H).
Example 99
2-Dimethylamino-N- [4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]- benzamide trifluoro acetate
Figure imgf000075_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 2- dimethylamino-benzoic acid. MS: 461.3 (M+H).
Example 100 N-[2-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-6-morpholin-4-yl-nicotinamide
Figure imgf000075_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 'Jbipyrrolidinyl- l'-yl)-phenylamine with 6-morpholin-4- yl-nicotinic acid. MS: 450.5 (M+H).
Example 101
5-Methyl-2-phenyl-2H-[ 1 ,2,3]triazole-4-carboxylic acid [2-methyl-4-(2-methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenyl]-amide
Figure imgf000076_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 5-methyl-2- phenyl-2H-[l,2,3]triazole-4-carboxylic acid. MS: 445.4 (M+H).
Example 102
2,3-Dihydro-benzofuran-5-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)- phenyl]-amide
Figure imgf000076_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2,3-dihydro- benzofuran-5-carboxylic acid. MS: 406.4 (M+H).
Example 103
Thiophene-2-carboxylic acid [4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -amide trifluoroacetate
Figure imgf000076_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with thiophene-2-carboxylic acid. MS: 356.2 (M+H).
Example 104 4-Methanesulfonyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000076_0004
.CF3CO2H The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 4-methanesulfonyl-benzoyl chloride. MS: 428.2 (M+H).
Example 105
4-Benzoyl- 1 H-pyrrole-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ?-yl)- phenyl]-amide
Figure imgf000077_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-benzoyl-lH- pyrrole-2-carboxylic acid. MS: 457.4 (M+H).
Example 106 l-Isopropyl-lH-benzotriazole-S-carboxylic acid [2 -methyl-4-(2 -methyl- [1,3 'Jbipyrrolidinyl-
1 '-yl)-phenyl] -amide
Figure imgf000077_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 1-isopropyl-lH- benzotriazole-5-carboxylic acid. MS: 447.3 (M+H).
Example 107
2-Methanesulfonyl-N- [4-(2 -methyl- [ 1 ,3 ']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl] - acetamide trifluoroacetate
Figure imgf000077_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 2- methanesulfonyl acetic acid. MS: 434.1 (M+H). Example 108
2-Dimethylamino-N- [4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000078_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-dimethylamino benzoic acid. MS: 393.3 (M+H).
Example 109
3 -Fluoro-N- [4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl] -benzamide trifluoroacetate
Figure imgf000078_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 3-fluoro- benzoyl chloride. MS: 436.2 (M+H). Example 110
4-Chloro-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -benzamide trifluoroacetate
Figure imgf000078_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-chloro-benzoyl chloride. MS: 384.2 (M+H).
Example 111 Quinoline-3-carboxylic acid [2-methyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide
Figure imgf000079_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with quinoline-3 - carboxylic acid. MS: 415.3 (M+H).
Example 112 4-Imidazol- 1 -yl-N-[2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide
Figure imgf000079_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 4-imidazol- 1 -yl benzoic acid. MS: 430.5 (M+H).
Example 113 lH-Indole-6-carboxylic acid [2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-amide
Figure imgf000079_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with lH-indole-6- carboxylic acid. MS: 403.3 (M+H).
Example 114
6-Methoxy- lH-indazole-3 -carboxylic acid [2 -methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)- phenylj-amide
Figure imgf000079_0004
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 6-methoxy-lH- indazole-3-carboxylic acid. MS: 434.3 (M+H).
Example 115
2-Methanesulfonyl-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-acetamide trifluoroacetate
Figure imgf000080_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-methanesulfonyl acetic acid. MS: 366.2 (M+H).
Example 116
2-Dimethylamino-N- [4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]- acetamide trifluoroacetate
Figure imgf000080_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 2- dimethylamino acetic acid. MS: 399.3 (M+H).
Example 117
4-Cyano-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]-benzamide trifluoroacetate
Figure imgf000080_0003
.CF3CO2H
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 4-cyano- benzoyl chloride. MS: 443.2 (M+H). Example 118 N-[4-(2-Methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl] -nicotinamide trifluoroacetate
Figure imgf000081_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with nicotinic acid. MS: 351.2 (M+H).
Example 119
Imidazo[ 1 ,2-a]pyridine-8-carboxylic acid [4-(2-methyl-[ 1 ,3']bipyrrolidinyl-l'-yl)-2- trifluoromethyl-phenyl] -amide trifluoroacetate
Figure imgf000081_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenylamine with imidazo[l,2-a]pyridine-8-carboxylic acid. MS: 458.2 (M+H).
Example 120 N-[4-(2-Methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-2-phenoxy-acetamide trifluoroacetate
Figure imgf000081_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with phenoxy-acetic acid. MS: 380.2 (M+H).
Example 121 4-Methoxy-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000081_0004
.CF3CO2H The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 4-methoxy-benzoyl chloride. MS: 380.2 (M+H).
Example 122
2-Oxo-2,3-dihydro-lH-benzoimidazole-5-carboxylic acid [2-methyl-4-(2-methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-amide
Figure imgf000082_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2-oxo-2,3- dihydro-lH-benzoimidazole-S-carboxylic acid. MS: 420.3 (M+H).
Example 123
N-[3-Methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-4-morpholin-4-ylmethyl- benzamide trifluoroacetate
Figure imgf000082_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 3 -methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with 4-morpholin-4- ylmethyl-benzoyl chloride. MS: 463.3 (M+H).
Example 124 N-[2-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-4-(l-propoxy-ethyl)-benzamide
Figure imgf000082_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 'Jbipyrrolidinyl- l'-yl)-phenylamine with 4-(l-propoxy- ethyl)-benzoic acid. MS: 463.3 (M+H).
Example 125 N-[4-(2-Methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]-nicotinamide trifluoroacetate
Figure imgf000083_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with nicotinic acid. MS: 419.2 (M+H).
Example 126
4-[(4,6-Dimethyl-pyrimidin-2-yl)-methyl-amino]-N-[2-methyl-4-(2-methyl- [ 1 ,3 'Jbipyrrolidinyl- l'-yl)-pheny 1] -benzamide
Figure imgf000083_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-[(4,6-dimethyl- pyrimidin-2-yl)-methyl-amino]-benzoic acid. MS: 499.5 (M+H).
Example 127 3,5-Dichloro-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000083_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3,5-dichloro- benzoic acid. MS: 432.2 (M+H).
Example 128
3 -Dimethylamino-N- [4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl] - benzamide trifluoroacetate
Figure imgf000084_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 3- dimethylamino-benzoic acid. MS: 461.3 (M+H).
Example 129
3-Methoxy-N-[3-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000084_0002
.CF3CO2H
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-methoxy- benzoic acid. MS: 394.2 (M+H).
Example 130
4-Dimethylamino-N-[3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000084_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with A- dimethylamino-benzoic acid. MS: 407.3 (M+H).
Example 131 2,4-Dimethyl-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000084_0004
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 2,4-dimethyl-benzoyl chloride. MS: 378.2 (M+H).
Example 132
4-Methanesulfonyl-N- [4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]- benzamide trifluoroacetate
Figure imgf000085_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 4- methanesulfonyl-benzoic acid. MS: 496.2 (M+H).
Example 133
N-[4-(2-Methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-2-trifluoromethyl-phenyl]-2-phenoxy-acetamide trifluoroacetate
Figure imgf000085_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with phenoxy- acetic acid. MS: 448.2 (M+H).
Example 134
2,4-Dimethyl-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000085_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2,4-dimethyl- benzoyl chloride. MS: 392.2 (M+H). Example 135
Benzo[d]imidazo[2, 1 -b]thiazole-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl-
1 '-yl)-phenyl] -amide
Figure imgf000086_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [ 1 ,3 'Jbipyrrolidinyl- 1 '-yl)-phenylamine with benzo[d]imidazo[2,l-b]thiazole-2-carboxylic acid. MS: 460.4 (M+H).
Example 136
4-Methoxy-N-[4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenyl]-benzamide trifluoroacetate
Figure imgf000086_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-2-trifluoromethyl-phenylamine with 4- methoxy benzoic acid. MS: 448.2 (M+H). Example 137
N-[3-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-2-phenoxy-acetamide trifluoroacetate
Figure imgf000086_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with phenoxy-acetic acid. MS: 394.3 (M+H).
Example 138 3-Methoxy-N-[4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000087_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-methoxy-benzoic acid. MS: 380.2 (M+H).
Example 139
(E)-N-[3-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-3-pyridin-3-yl-acrylamide trifluoroacetate
Figure imgf000087_0002
.CF3CO2H
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-pyridin-3-yl- acrylic acid. MS: 391.3 (M+H).
Example 140
(E)-N-[2-Methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-3-pyridin-3-yl-acrylamide trifluoroacetate
Figure imgf000087_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-pyridin-3-yl- acrylic acid. MS: 391.3 (M+H).
Example 141 2,4-Dimethyl-N-[3-methyl-4-(2-methyl-[l ,3']bipyrrolidinyl-l '-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000087_0004
.CF3CO2H The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 2,4-dimethyl- benzoyl chloride. MS: 392.3 (M+H).
Example 142 N-[2-Methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-4-[ 1 ,2,4]triazol-l -yl-benzamide
Figure imgf000088_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 4-[l,2,4]triazol- 1-yl-benzoic acid. MS: 431.3 (M+H). Example 143
3-Fluoro-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000088_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 3-fluoro-benzoyl chloride. MS: 382.2 (M+H).
Example 144
3,5-Dichloro-N-[2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenyl]-benzamide trifluoroacetate
Figure imgf000088_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 3,5-dichloro- benzoyl chloride. MS: 432.2 (M+H).
Example 145 N-[3-Methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-nicotinamide trifluoroacetate
Figure imgf000089_0001
The title compound was prepared in a manner substantially the same as example 1 by coupling 3-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with nicotinic acid. MS: 365.2 (M+H).
Example 146
5 -Methoxy- 1 H-indole-2-carboxylic acid [2-methyl-4-(2-methyl-[ 1 ,3']bipyrrolidinyl- 1 ?-yl)- phenyl]-amide
Figure imgf000089_0002
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2 -methyl- [1, 3 ']bipyrrolidinyl-r-yl)-phenylamine with 5 -methoxy- IH- indole-2-carboxylic acid. MS: 433.2 (M+H).
Example 147 N- [2-M ethyl-4-(2 -methyl- [ 1 ,3']bipyrrolidinyl- 1 '-yl)-phenyl]-6-pyrazol- 1 -yl-nicotinamide
Figure imgf000089_0003
The title compound was prepared in a manner substantially the same as example 1 by coupling 2-methyl-4-(2-methyl-[l,3']bipyrrolidinyl-r-yl)-phenylamine with 6-pyrazol-l-yl- nicotinic acid. MS: 431.4 (M+H).
Biological Examples Example 148
This Example demonstrates the efficacy of compounds of this invention as H3 receptor ligands. The compounds of this invention have been demonstrated to displace [ H]- Methylhistamine radioligand binding to mammalian cell membranes expressing rhesus (Macacca Mulatta) H3 receptor. These compounds display rhesus H3 affinity constants (Ki) in the range of 1 μM to <1 nM. Additionally, the compounds of this invention have been demonstrated by GTPγS radioligand binding assay to inhibit rhesus H3 constitutive functional activity in cell membranes. This inhibition of basal rhesus H3-mediated GTPγS radioligand binding demonstrates that the compounds of this invention find utility as inverse agonists. These compounds decreased rhesus H3 GTPγS radioligand binding by 0-40% below basal levels.
Rhesus H3 membranes were prepared from the FIp-In T-REx 293 Cell Line (Invitrogen) stably transfected with pcDNA5/FRT/TO (Invitrogen) containing the rhesus monkey (Macacca Mulatta) 445 amino acid H3 receptor. (Genbank #AY231164). Stably transfected cultures were amplified in tissue culture flasks by standard tissue culture methods and induced to express rhesus H3 by exposure to 500 ng/ml tetracycline (Cellgro) for 24 hours. After induction, cells were dissociated from flasks utilizing Cell Stripper (Cellgro). Cells were centrifuged (IK x g, 5 min) and pellet frozen in an ethanol-dry ice bath to disrupt cell membranes. Frozen cell pellet was re-suspended in 5 mM HEPES (pH 7.4, Invitrogen) at 10ml/ 1000 cm2 of harvested cells. The cell suspension was drawn through an 18 gauge needle (2-3x) followed by a 23 gauge needle (2-3x) to further disrupt cell membranes. The cell suspension was centrifuged (4OK x g, 30 min). Cell membrane pellet was re-suspended in 5 mM HEPES (pH 7.4, Invitrogen) at a final protein concentration of 10 mg/ml. Rhesus H3 membranes were stored under liquid nitrogen prior to use in [3H]-Methylhistamine and GTPγS radioligand binding assays.
Rhesus H3 radioligand binding assay was performed using rhesus H3 receptor membranes (prepared as described above), [3H]-Methylhistamine (Perkin Elmer) and WGA SPA beads (wheat germ agglutinin scintillation proximity assay) beads (Amersham). The assay was performed in 96-well Opti-Plates (Packard). Each reaction contained 50 μl rhesus H3 membranes (20-30 μg total protein), 50 μl WGA SPA beads (0.1 μg) and 50 μl of 83Ci/mmol [3H]-Methylhistamine (final concentration 2 nM) and 50 μl of tested compound. The compounds of this invention and/or vehicle were diluted with binding buffer from 10 mM DMSO stocks. Assay plates were sealed with TopSeal (Perkin Elmer) and mixed on shaker (25°C, 1 hour). Assay plates were read on TopCount scintillation counter (Packard). Results were analyzed by Hill transformation and Ki values were determined by Cheng-Prusoff equation. The observed binding data for a few of the representative compounds of this invention are summarized in Table 1. Table 1
Figure imgf000091_0001
Example 149
This Example illustrates that the stereochemistry of the compounds of this invention has an effect on the biological activity. A few of the representative compounds of this invention were used in this example to show this difference in biological activity based on the stereoisomeric form. All of the compounds of this Example were tested for H3 receptor ligand activity in accordance with the procedures as set forth in Example 148. The results are tabulated in Table 2.
Table 2
Figure imgf000091_0002
Example 150
This Example illustrates selective affinity of the compounds of this invention at H3 receptors and exhibit low activity at the MCH-I receptor site.
The H3 affinity of the compounds of this invention was measured in accordance with the procedures set forth in Example 148.
The activity of the compounds of this invention at the MCH-I receptor site, if any, was measured by the procedures as set forth below.
Test Compounds: The compounds of this invention were stored in a 96-well microtiter plates (1 μL, 10 mM, 100% DMSO). Each of the test sample was diluted with 249 μL of 100% DMSO (dilution 1 :250). The test compounds were further diluted 1 :4 (0.1% DMSO) during assay resulting in the final concentration of test compounds of this invention to be 10 μM. Negative Control: 40 μM of MCH-I in assay buffer with 0.4% DMSO were transferred to the dilution microtiter plates for control which resulted in final concentration of 10 μM. Blank: Assay buffer containing 0.4% DMSO were transferred to the dilution microtiter plates for blanks.
Assay Procedure: The filter plates with 250 mL of 0.5% PEI-solution/well were incubated for 2 hours at room temperature. PEI was removed by vacuum filtration just before pipetting (Univac Polyfiltronic/Whatman). The solution of the compound as prepared above (50 μL), or MCH-I (negative control) or Puffer/DMSO (positive control) were added to 96-well round bottom microtiter plate. Then 50 μl of [ 125J] -ligand solution was added followed by 100 μl of membrane suspension. The plates were closed with the lids, and incubated for 60 min. at 25°C. The samples were transferred to GF/B filter plate. The reaction mixture was removed by vacuum filtration, washed 4 x with 300 μl ice-cold washing buffer and the washing solution was removed by vacuum filtration. The rubber layer at the bottom of the plate was then removed and the filters were dried over night at room temperature. 25 μl of scintillation cocktail was added and the plates were sealed and, plate frames were added and incubated for 1 hour at room temperature. The radioactivity was then measured, settings 125J standard, 30 sec/well. From this the percent inhibition of ligand binding was measured. Results: In general the compounds of this invention exhibited a rhesus H3 binding ki value in the range of from about 400 nM to less than 1 nM, whereas the percent inhibition of ligand binding at MCH-I receptor was less than 40% at 10 μM concentration. This comparative Example demonstrates that the compounds of this invention can be more than thousand times more selective at H3 receptor site than at MCH-I receptor site. Example 151
This Example illustrates the study of efficacy of the compounds of this invention in enhancing the wakefulness in animal models.
Male Sprague Dawley rats (Charles River, France) weighing 250 ± 10 g were anaesthetized with ZoletilR 50 (60 mg/kg ip) and mounted in a stereotaxic apparatus. Cortical electrodes (small stainless steel screw electrodes of 0.9 mm in diameter) were screwed into the bone over the sensorimotor cortex (1.5 mm lateral to the median suture and 1.5 mm behind the fronto-parietal suture), the visual cortex (1.5 mm lateral to the median suture and 1.5 mm in front of the parietooccipital suture) and over the cerebellum (reference electrode). Cortical electrodes were attached to a connector (Winchester, 7-lead) and fixed with dental cement to the cranium.
After three weeks of post-operative recovery, animals were placed in plexiglass cylinders (60 cm diameter) with free access to food and water. The temperature of the room was kept constant (21 ± 1 0C) and lights were on from 7 a.m. to 7 p.m. The rats were recorded from 10 a.m. to 4 p.m. during three consecutive days: control day (Dl), drug day (D2) and post drug day (D3). Vehicle (Dl and D3) or drug (D2) were administered 15 min before the recording. Activity in sensorimotor and visual cortices were recorded by comparison with the reference electrode placed over the cerebellar cortex. Three stages were differentiated: wakefulness (W) characterized by low voltage fast electrocortical (ECoG) activity; NREM sleep (non rapid eye movement or slow wave sleep: SWS) characterized by an increase in electrocortical activity; development of high-amplitude slow waves with some bursts of sleep spindles;
REM sleep (rapid eye movement or paradoxical sleep: PS) characterized by hypersynchronization of the theta rhythm in the visual area.
Analysis of the ECoG signal was performed automatically by means of a computerized system discriminating between the various sleep phases using sequential spectral analysis of ten seconds periods (Deltamed's software "Coherence").
The compounds of this invention were dissolved in 0.6% MTC tween and administered by oral route (po). The volume of injection was 0.5ml/100g of body weight.
Two types of analysis were used to quantify the effects of the compounds of this invention on sleep-wakefulness variables: the one hour-period and the six hour-period analysis.
The results are expressed in minutes (one hour-period analysis) or as the percentage of the control values (100%). Statistical analysis of the data was carried out using the Student's t test for paired values to determine significant variations from control values.
Example 152 Stress-induced ultrasonic vocalizations test in adult rats
This Example illustrates the study of efficacy of the compounds of this invention as antidepressive agents in animal models. The procedure used was adapted from the technique described by Van Der Poel A.M, Noach E.J.K, Miczek K. A (1989) Temporal patterning of ultrasonic distress calls in the adult rat: effects of morphine and benzodiazepines. Psychopharmacology 97:147-8. Rats were placed for a training session in a cage with a stainless steel grid floor (MED Associates, Inc., St. Albans, VT). Four electric shocks (0.8 mA, 3s) were delivered every 7s and ultrasonic vocalizations (UV, 22KHz) were subsequently recorded with the Ultravox system (Noldus, Wageningen, The Netherlands) during 2 min. A modified ultrasound detector (Mini-3 bat model) connected to a microphone was used to transform ultrasonic sound into audible sound. The signal was then filtered and sent to a computer where the Ultravox software recorded each bout of UV that lasted more than 10ms. Rats were selected on the basis of their UV duration (>40s) and subjected to the test, 4h after training. For the test, rats were placed in the same cage as that used for training. One electric shock (0.8 mA, 3s) was delivered and UV (duration and frequency) were subsequently recorded with the Ultravox system during 2 min. The compounds of this invention were administered p.o. 60 min before testing. Example 153
Forced-swimming test in rats
This Example further illustrates the study of efficacy of the compounds of this invention as antidepressive agents in animal models.
The procedure was a modification of that described by Porsolt et al. (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-2. Rats were placed in individual glass cylinder (40 cm height, 17 cm diameter) containing water (210C) to a height of 30 cm. Two swimming sessions were conducted (a 15-min training session followed 24h later by a 6-min test). After each swimming session, rats were placed under a heating lamp to avoid hypothermia. The duration of immobility was measured during the 6-min test. The compounds of this invention were administered p.o. twice (15 min after training session and 60 min before the test).
Although the invention has been illustrated by certain of the preceding examples, it is not to be construed as being limited thereby; but rather, the invention encompasses the generic area as hereinbefore disclosed. Various modifications and embodiments can be made without departing from the spirit and scope thereof.

Claims

CLAIMSWhat is claimed is:
1. A compound of formula (I) :
Figure imgf000095_0001
wherein
R, R1, R2 and R3 are the same or different and independently of each other chosen from hydrogen, (Ci-C4)alkyl or CF3; R4 is selected from the group consisting of dimethylaminomethyl, methanesulfonylmethyl, phenoxymethyl, vinylbenzene, ethynylbenzene, vinylpyridine, phenyl, benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro- benzofuranyl, benzodioxolyl, oxo-chromenyl, dihydrobenzo-dioxinyl, dioxo- tetrahydro- 1 H-benzo [e] diazepinyl, imidazopyridinyl, benzotriazolyl, benzoimidazolyl, oxo-dihydro-benzoimidazolyl, indolyl, indazolyl, naphthyridinyl, quinolinyl, benzoimidazothiazolyl, pyridinyl, pyrimidinyl, pyrrolyl, triazolyl, thienyl, thiazolyl, tetrahydrofuranyl or pyrrolidinyl; wherein said R4 is optionally substituted one or more times with a substituent selected from halogen, hydroxy, methyl, ethyl, isopropyl, propoxyethyl, phenyl, benzoyl, methoxy, difluoromethoxy, CF3, CN, acetyl, methanesulfonyl, sulfamoyl, dimethylamino, N-formyl-methylamino, 2-hydroxyethylamino,
2-methoxyethylamido, benzyloxymethyl, carboxyphenoxy, pyrazolyl, 3,5- dimethyl-pyrazolyl, imidazolyl, triazolyl, oxazolyl, pyridinyl, oxo-dihydro-pyridinyl, pyrimidinyl-methylamino, N-acetyl-piperidinyl, morpholinyl, morpholinylmethyl or 2-oxo-pyrrolidinyl; or a salt thereof or an enantiomer or a diastereomer thereof.
2. The compound according to claim 1 , wherein R is methyl; R2 is methyl or CF3; Ri and R3 are hydrogen.
3. The compound according to claim 1 , wherein R is methyl; Ri is methyl or CF3; R2 and R3 are hydrogen.
4. The compound according to claim 1 , wherein R4 is phenyl or phenyl substituted with one or more groups selected from fluorine, chlorine, methyl, isopropyl, propoxyethyl, CF3, CN, methoxy, difluoromethoxy, methanesulfonyl, sulfamoyl, dimethylamino, N-formyl-methylamino, carboxyphenoxy, oxo-dihydro-pyridinyl, pyrimidinyl- methylamino, pyrazolyl, 3,5-dimethyl-pyrazolyl, imidazolyl, triazolyl, oxazolyl, N-acetyl-piperidinyl, morpholinylmethyl or 2-oxo-pyrrolidinyl.
5. The compound according to claim 1 , wherein R4 is selected from benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro-benzofuranyl, benzodioxolyl, dihydrobenzo- dioxinyl, dioxo-tetrahydro-lH-benzo[e]diazepinyl or oxo-chromenyl, which is optionally substituted one or more times with chlorine, methyl or methoxy.
6. The compound according to claim 1 , wherein R4 is selected from dimethylaminomethyl, methanesulfonylmethyl, phenoxymethyl, vinylbenzene, ethynylbenzene or vinylpyridine, which is optionally substituted one or more times with fluorine.
7. The compound according to claim 1 , wherein R4 is pyridinyl or pyrimidinyl, which is optionally substituted one or more times with chlorine, methyl, 2-hydroxyethylamino, 2-methoxyethylamido, benzyloxymethyl or morpholinyl.
8. The compound according to claim 1 , wherein R4 is selected from imidazopyridinyl, benzotriazolyl, benzoimidazolyl, oxo-dihydro-benzoimidazolyl, indolyl, indazolyl, naphthyridinyl, quinolinyl or benzoimidazothiazolyl, which is optionally substituted one or more times with fluorine, chlorine, hydroxy, methyl, isopropyl, methoxy or pyridinyl.
9. The compound according to claim 1 , wherein R4 is selected from pyrrolyl, triazolyl, thienyl or thiazolyl, which is optionally substituted one or more times with methyl, phenyl, benzoyl or pyridinyl.
10. The compound according to claim 1, wherein R4 is selected from tetrahydrofuranyl or pyrrolidinyl, which is optionally substituted one or more times with acetyl.
11. The compound according to claim 1 which is having the formula (II):
Figure imgf000097_0001
wherein R, Ri, R2, R3 and R4 are as defined in claim 1.
12. A pharmaceutical composition comprising a compound of formula (I):
Figure imgf000097_0002
wherein R, R1, R2 and R3 are the same or different and independently of each other chosen from hydrogen, (Ci-C4)alkyl or CF3; R4 is selected from the group consisting of dimethylaminomethyl, methanesulfonylmethyl, phenoxymethyl, vinylbenzene, ethynylbenzene, vinylpyridine, phenyl, benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro- benzofuranyl, benzodioxolyl, oxo-chromenyl, dihydrobenzo-dioxinyl, dioxo- tetrahydro-lH-benzo[e]diazepinyl, imidazopyridinyl, benzotriazolyl, benzoimidazolyl, oxo-dihydro-benzoimidazolyl, indolyl, indazolyl, naphthyridinyl, quinolinyl, benzoimidazothiazolyl, pyridinyl, pyrimidinyl, pyrrolyl, triazolyl, thienyl, thiazolyl, tetrahydrofuranyl or pyrrolidinyl; wherein said R4 is optionally substituted one or more times with a substituent selected from halogen, hydroxy, methyl, ethyl, isopropyl, propoxyethyl, phenyl, benzoyl, methoxy, difluoromethoxy, CF3, CN, acetyl, methanesulfonyl, sulfamoyl, dimethylamino, N-formyl-methylamino, 2-hydroxyethylamino, 2-methoxyethylamido, benzyloxymethyl, carboxyphenoxy, pyrazolyl, 3,5- dimethyl-pyrazolyl, imidazolyl, triazolyl, oxazolyl, pyridinyl, oxo-dihydro-pyridinyl, pyrimidinyl-methylamino, N-acetyl-piperidinyl, morpholinyl, morpholinylmethyl or 2-oxo-pyrrolidinyl; or a pharmaceutically acceptable salt thereof or an enantiomer or a diastereomer thereof in combination with at least one pharmaceutically acceptable excipient, diluent or a carrier.
13. The composition according to claim 12, wherein R4 is phenyl or phenyl substituted with one or more groups selected from fluorine, chlorine, methyl, isopropyl, propoxyethyl, CF3, CN, methoxy, difluoromethoxy, methanesulfonyl, sulfamoyl, dimethylamino, N-formyl-methylamino, carboxyphenoxy, oxo-dihydro-pyridinyl, pyrimidinyl-methylamino, pyrazolyl, 3,5-dimethyl-pyrazolyl, imidazolyl, triazolyl, oxazolyl, N-acetyl-piperidinyl, morpholinylmethyl or 2-oxo-pyrrolidinyl.
14. The composition according to claim 12, wherein R4 is selected from benzofuranyl, dihydro-benzofuranyl, oxo-tetrahydro-benzofuranyl, benzodioxolyl, dihydrobenzo- dioxinyl, dioxo-tetrahydro-lH-benzo[e]diazepinyl or oxo-chromenyl, which is optionally substituted one or more times with chlorine, methyl or methoxy.
15. The composition according to claim 12, wherein R4 is pyridinyl or pyrimidinyl, which is optionally substituted one or more times with chlorine, methyl, 2-hydroxyethylamino, 2-methoxyethylamido, benzyloxymethyl or morpholinyl.
16. The composition according to claim 12, wherein the compound is having the formula (II):
Figure imgf000099_0001
wherein R, R1, R2, R3 and R4 are as defined in claim 12.
17. Use of a compound of formula (I) according to claim 1 , optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for the treatment of a disease selected from the group consisting of sleep related disorder, dementia, Alzheimer's disease, multiple sclerosis, cognitive disorder, attention deficit hyperactivity disorder and depression.
18. The use according to claim 17, wherein the sleep disorder is selected from the group consisting of narcolepsy, circadian rhythm sleep disorder, obstructive sleep apnea, periodic limb movement and restless leg syndrome, excessive sleepiness and drowsiness due to medication side-effect.
19. The use according to claim 17, wherein the sleep disorder is narcolepsy.
20. The use according to claim 17, wherein the disease is cognitive disorder.
21. The use according to claim 17, wherein the disease is Alzheimer's disease.
22. The use according to claim 17, wherein the disease is depression.
23. The use according to claim 17, wherein the disease is dementia.
24. The use according to claim 17, wherein R4 is phenyl or phenyl substituted with one or more groups selected from fluorine, chlorine, methyl, isopropyl, propoxy ethyl, CF3, CN, methoxy, difluoromethoxy, methanesulfonyl, sulfamoyl, dimethylamino, N-formyl-methylamino, carboxyphenoxy, oxo-dihydro-pyridinyl, pyrimidinyl- methylamino, pyrazolyl, 3,5-dimethyl-pyrazolyl, imidazolyl, triazolyl, oxazolyl, N-acetyl-piperidinyl, morpholinylmethyl or 2-oxo-pyrrolidinyl.
25. The use according to claim 17, wherein the compound is having the formula (II):
Figure imgf000100_0001
wherein R, R1, R2, R3 and R4 are as defined in claim 1.
PCT/US2008/079760 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof WO2009052065A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CA2702482A CA2702482C (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
PL08839473T PL2212282T3 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
AT08839473T ATE525350T1 (en) 2007-10-17 2008-10-14 SUBSTITUTED N-PHENYL-BIPYRROLIDINECARBONIC ACID AMIDES AND THEIR THERAPEUTIC USE
JP2010530052A JP5255644B2 (en) 2007-10-17 2008-10-14 Substituted N-phenyl-bipyrrolidinecarboxamides and therapeutic uses thereof
AU2008312638A AU2008312638B2 (en) 2007-10-17 2008-10-14 Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
SI200830482T SI2212282T1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
ES08839473T ES2374116T3 (en) 2007-10-17 2008-10-14 N-PHENYL-BIPIRROLIDINE SUBSTITUTED CARBOXAMIDS AND THERAPEUTIC USE.
DK08839473.9T DK2212282T3 (en) 2007-10-17 2008-10-14 Substituted N-phenylbipyrrolidine carboxamides and therapeutic use thereof
RU2010119560/04A RU2477719C2 (en) 2007-10-17 2008-10-14 Substituted n-phenylbipyrrolidine carboxamides and therapeutic use thereof
EP08839473A EP2212282B1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
CN2008801211996A CN101903339B (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
MX2010004094A MX2010004094A (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof.
NZ584688A NZ584688A (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
BRPI0818626A BRPI0818626A2 (en) 2007-10-17 2008-10-14 substituted n-phenyl bipyrrolidine carboxamides and therapeutic use thereof
US12/724,035 US8618159B2 (en) 2007-10-17 2010-03-15 Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
IL205003A IL205003A0 (en) 2007-10-17 2010-04-11 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
MA32846A MA31855B1 (en) 2007-10-17 2010-05-17 SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THEIR THERAPEUTIC USE
HK11100255.7A HK1146054A1 (en) 2007-10-17 2011-01-12 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
HR20110953T HRP20110953T1 (en) 2007-10-17 2011-12-19 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98060107P 2007-10-17 2007-10-17
US60/980,601 2007-10-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/724,035 Continuation US8618159B2 (en) 2007-10-17 2010-03-15 Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Publications (1)

Publication Number Publication Date
WO2009052065A1 true WO2009052065A1 (en) 2009-04-23

Family

ID=40243633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/079760 WO2009052065A1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Country Status (26)

Country Link
US (1) US8618159B2 (en)
EP (1) EP2212282B1 (en)
JP (1) JP5255644B2 (en)
KR (1) KR20100092441A (en)
CN (1) CN101903339B (en)
AT (1) ATE525350T1 (en)
AU (1) AU2008312638B2 (en)
BR (1) BRPI0818626A2 (en)
CA (1) CA2702482C (en)
CO (1) CO6190616A2 (en)
CY (1) CY1112683T1 (en)
DK (1) DK2212282T3 (en)
ES (1) ES2374116T3 (en)
HK (1) HK1146054A1 (en)
HR (1) HRP20110953T1 (en)
IL (1) IL205003A0 (en)
MA (1) MA31855B1 (en)
MX (1) MX2010004094A (en)
MY (1) MY149650A (en)
NZ (1) NZ584688A (en)
PL (1) PL2212282T3 (en)
PT (1) PT2212282E (en)
RU (1) RU2477719C2 (en)
SI (1) SI2212282T1 (en)
WO (1) WO2009052065A1 (en)
ZA (1) ZA201001946B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065803A1 (en) * 2008-12-05 2010-06-10 Sanofi-Aventis Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
WO2011143148A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
WO2011143161A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
WO2011143162A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
WO2011143145A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
US8088808B2 (en) 2007-10-17 2012-01-03 Sanofi Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
US8217052B2 (en) 2008-12-05 2012-07-10 Sanofi Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
US8222290B2 (en) 2007-10-17 2012-07-17 Sanofi Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof
US8227504B2 (en) 2007-10-17 2012-07-24 Sanofi Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof
JP2013526528A (en) * 2010-05-11 2013-06-24 サノフイ Substituted N-heteroaryltetrahydro-isoquinoline derivatives, their preparation and therapeutic use
EP2714941A1 (en) * 2011-05-24 2014-04-09 The Wistar Institute Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1
US8735385B2 (en) 2010-05-11 2014-05-27 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
US9458110B2 (en) 2013-02-28 2016-10-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081384A1 (en) * 2010-05-11 2012-08-29 Sanofi Aventis N- PHENYL BIPIRROLIDINES SUBSTITUTED, PREPARATION AND THERAPEUTIC USE OF THE SAME

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037257A1 (en) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
WO2006107661A1 (en) * 2005-04-01 2006-10-12 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2007005503A1 (en) * 2005-07-01 2007-01-11 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2007048595A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (en) * 2000-10-17 2002-06-25 Schering Corp NON-IMIDAZOLE COMPOUNDS AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR
DE10306250A1 (en) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals
PL1861360T3 (en) 2005-03-17 2010-04-30 Lilly Co Eli Pyrrolidine derivatives as histamine h3 receptor antagonists
EP2212283B1 (en) * 2007-10-17 2011-09-21 Sanofi Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
ES2392122T3 (en) * 2007-10-17 2012-12-04 Sanofi N-phenyl-pyrrolidinylmethylpyrrolidin substituted amides and therapeutic use thereof
MX2010003948A (en) 2007-10-17 2010-04-30 Sanofi Aventis Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037257A1 (en) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
WO2006107661A1 (en) * 2005-04-01 2006-10-12 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2007005503A1 (en) * 2005-07-01 2007-01-11 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
WO2007048595A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252824B2 (en) 2007-10-17 2012-08-28 Sanofi Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
US8088808B2 (en) 2007-10-17 2012-01-03 Sanofi Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
US8222290B2 (en) 2007-10-17 2012-07-17 Sanofi Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof
US8227504B2 (en) 2007-10-17 2012-07-24 Sanofi Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof
CN102239168A (en) * 2008-12-05 2011-11-09 赛诺菲 Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
CN102239168B (en) * 2008-12-05 2014-03-12 赛诺菲 Substituted piperidine spiro pyrrolidinone and piperidinones used as H3 modulators
US8604046B2 (en) 2008-12-05 2013-12-10 Sanofi Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
WO2010065803A1 (en) * 2008-12-05 2010-06-10 Sanofi-Aventis Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators
US8383814B2 (en) 2008-12-05 2013-02-26 Sanofi Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
US8217052B2 (en) 2008-12-05 2012-07-10 Sanofi Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
US8227481B2 (en) 2008-12-05 2012-07-24 Sanofi Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
JP2013529197A (en) * 2010-05-11 2013-07-18 サノフイ Substituted N-alkyl and N-acyltetrahydro-isoquinoline derivatives, their preparation and therapeutic use
US8735385B2 (en) 2010-05-11 2014-05-27 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
JP2013526528A (en) * 2010-05-11 2013-06-24 サノフイ Substituted N-heteroaryltetrahydro-isoquinoline derivatives, their preparation and therapeutic use
JP2013526526A (en) * 2010-05-11 2013-06-24 サノフイ Substituted N-heteroaryl spirolactam bipyrrolidines, their preparation and therapeutic use
JP2013526529A (en) * 2010-05-11 2013-06-24 サノフイ Substituted N-heteroarylbipyrrolidinecarboxamides, their preparation and therapeutic use
WO2011143162A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
JP2013529198A (en) * 2010-05-11 2013-07-18 サノフイ Substituted N-heterocycloalkylbipyrrolidinylphenylamide derivatives, their preparation and therapeutic use
WO2011143161A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
US8623877B2 (en) 2010-05-11 2014-01-07 Sanofi Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
WO2011143148A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
US9533995B2 (en) 2010-05-11 2017-01-03 Sanofi Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
WO2011143145A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
US8754095B2 (en) 2010-05-11 2014-06-17 Sanofi Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
US8796278B2 (en) 2010-05-11 2014-08-05 Sanofi Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
US8859588B2 (en) 2010-05-11 2014-10-14 Sanofi Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
US8871788B2 (en) 2010-05-11 2014-10-28 Sanofi Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
US9453023B2 (en) 2010-05-11 2016-09-27 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
US9309212B2 (en) 2011-05-24 2016-04-12 The Wistar Institute Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1
EP2714941A4 (en) * 2011-05-24 2014-12-03 Wistar Inst Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1
EP2714941A1 (en) * 2011-05-24 2014-04-09 The Wistar Institute Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1
US9458110B2 (en) 2013-02-28 2016-10-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors

Also Published As

Publication number Publication date
BRPI0818626A2 (en) 2015-09-29
RU2010119560A (en) 2011-11-27
PL2212282T3 (en) 2012-02-29
JP2011500696A (en) 2011-01-06
AU2008312638A1 (en) 2009-04-23
CA2702482A1 (en) 2009-04-23
CN101903339B (en) 2012-06-27
PT2212282E (en) 2012-01-09
NZ584688A (en) 2011-12-22
ZA201001946B (en) 2010-10-27
DK2212282T3 (en) 2012-01-23
ATE525350T1 (en) 2011-10-15
CN101903339A (en) 2010-12-01
MY149650A (en) 2013-09-30
CA2702482C (en) 2012-11-27
HK1146054A1 (en) 2011-05-13
RU2477719C2 (en) 2013-03-20
MA31855B1 (en) 2010-11-01
ES2374116T3 (en) 2012-02-13
US8618159B2 (en) 2013-12-31
JP5255644B2 (en) 2013-08-07
IL205003A0 (en) 2010-11-30
CO6190616A2 (en) 2010-08-19
EP2212282A1 (en) 2010-08-04
US20100173897A1 (en) 2010-07-08
CY1112683T1 (en) 2016-02-10
AU2008312638B2 (en) 2013-05-16
SI2212282T1 (en) 2012-01-31
EP2212282B1 (en) 2011-09-21
HRP20110953T1 (en) 2012-01-31
MX2010004094A (en) 2010-04-30
KR20100092441A (en) 2010-08-20

Similar Documents

Publication Publication Date Title
EP2212282B1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
EP2212283B1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
EP2205558B1 (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
EP2215058B1 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
EP2373659A1 (en) Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
EP2569294B1 (en) Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880121199.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08839473

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12010500695

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2017/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 205003

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2702482

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/004094

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008312638

Country of ref document: AU

Ref document number: 584688

Country of ref document: NZ

Ref document number: 2010530052

Country of ref document: JP

Ref document number: 10044768

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2010000230

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: PI 2010001276

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 2008839473

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008312638

Country of ref document: AU

Date of ref document: 20081014

Kind code of ref document: A

Ref document number: 20107010545

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010119560

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0818626

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100414